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Background: Warfarin is the most commonly used drug in the management of thromboembolic 
disease. However, there is a huge variability in the management of warfarin affecting the 
international normalized ratio (INR). Many genetic-association studies have reported on European 
and Asian populations which has led to the designing of specific algorithms that are now being used 
to assist in warfarin dosing. However, very few or no studies have looked at the pharmacogenetics of 
warfarin in African populations, yet, huge differences in dosage requirements to reach the same INR 
have been observed. We set out to investigate genetic factors affecting warfarin therapy in South 
African black (SAB) and Mixed Ancestry (MA) participants. 
 
Methods: We recruited consenting participants from Groote Schuur Hospital and Gugulethu 
Community Health Centre comprising 263 of Mixed ancestry (MA) descent and 109 of South 
African black (SAB) descent. Demographic data, clinical information and 5ml of blood for genetic 
characterization was obtained from participants. DNA was extracted from the blood and 
genotyped using PCR/RFLP and Sanger sequencing for 5 single nucleotide polymorphisms (SNPs), 
VKORC1 c.-1639G>A, VKORC1 c.1173C>T, VKORC1 c.3730G>A, GGCX c.1218C>T and GGCX 
c.1242C>T. 
 
Results: We report an association of age with warfarin dose, where, older patients had lower 
dose requirements (p>0.001 in MA; p>0.042 in SAB). Higher BMI was associated with increased 
stabilizing dose in the MA group (p=0.003). The SNP VKORC1 c.-1639G>A was associated with 
stabilizing dose only in MA (p>0.003), with carriers of the A/A genotype requiring lower dosages 
(18 ± 14 mg/week) compared to G/G (38 ± 14 mg/week). 
 
Conclusion: We conclude that environmental and genetic factors may play a role in the way 
South African patients respond to warfarin. Particularly, it appears as if MA and SAB population 
group have different underlying genetic markers for warfarin response. This knowledge in 
warfarin pharmacogenomics could help in the judicious use of warfarin in South African patients. 
However, more genetic markers need to be characterized to understand the profiles of genetic 
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To assess drug efficacy, dose and safety; it is important to consider inter-individual variations in 
pharmacokinetics (drug absorption, distribution, metabolism and excretion) and 
pharmacodynamics (drug targets) (Pirmohamed, 2013). Variations in drug response such as 
adverse drug reactions have led to differences in the efficacy of drug treatments among 
individuals (Kudzi et al., 2011). Pharmacogenetics and pharmacogenomics, makes it possible to 
identify individuals likely to benefit or not from a particular treatment and those who may 
experience life threatening adverse reactions from a particular drug (Giacomini et al., 2007). 
Pharmacogenomics incorporated into drug discovery enables the identification of new drug 
targets, reduction in treatment costs, improvement in understanding on the mechanism of 
action of drugs to improve efficacy and reduce adverse drug reactions (ADRs) (Kudzi et al., 2015). 
In addition, pharmacogenetics may assist in improving the ability of a country to respond to 
population specific disease threats and enable improved policy decisions on interventions for 
population specific healthcare system (Pang et al., 2009). Unfortunately for African populations 
there is limited information available on the pharmacogenetics of indigenous African populations 
(Marsh, 2008) making ADRs inevitable and more common among the African population 
(Arwood et al., 2017). In addition, more clinical trials are carried in populations that do not 
include Africans, thus, in most cases ADRs are encountered post marketing when the drug has 
made it into Africa for use. For example, the use of efavirenz in sub-Saharan Africa has resulted 
in frequent observations of ADRs (Masimirembwa et al., 2016). 
 
1.1.1 Adverse drug reactions 
 
Adverse drug reactions (ADRs) are complications caused by drug treatment which may result in 
morbidity, mortality and hospitalization in patients, more especially in patients living in 
developing countries like South Africa where not only is the patient affected but also the 
healthcare system is affected severely by ADRs (Dandara et al., 2011; Lövborg et al., 2012; 
Bracken et al., 2017). A systematic review by Smyth et al. (2012) reported that ADRs cause 
hospitalization in children in incidences ranging from 0.6-16.8% (Smyth et al., 2012). This rate is 
similar to adult hospitalization rate reported by Davies et al. (2009) of 14.7% in Liverpool
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(Davies et al., 2009). The incidence rates suggest the importance of studying how to avoid 
(prevent) ADRs (Ferner and Aronson, 2010). In sub-Saharan Africa, Masimirembwa et al. (2016) 
reported on the ADRs caused by efavirenz causing neuropsychiatric conditions (Masimirembwa 
et al., 2016). It is important to note that hospitalisation due to ADRs is an additional burden that 
consumes scarce resources in poor and developing countries. According to World Health 
Organisation (WHO) (2009), in developing countries, one out of ten patients is harmed during 
hospital treatment caused by unsafe medical care (WHO, 2009, 2011). 
 
In a meta-analysis conducted by Hakkarainen et al. (2012) it was concluded that healthcare 
systems are significantly affected by avoidable ADRs which result in morbidity among patients 
(Hakkarainen et al., 2012). They further estimated that half of all ADRs may be avoidable in 52% 
of outpatients and 45% of adult patients (Hakkarainen et al., 2012). Similar findings were 
reported by Mouton et al. (2016) in a South African study that 45% of ADRs that led to 
administration could be prevented (Mouton et al., 2016). However, the lack of commonly 
accepted terms/definitions has made the study of how to avoid ADRs complex (Ferner and 
Aronson, 2010). This study is focussing on the use of warfarin, a vitamin K antagonist, and factors 
affecting warfarin therapy. 
 
1.2 Vitamin K antagonists 
 
Vitamin k antagonists (VKAs) have been the primary oral anticoagulant drugs for the past 
decades in the treatment and prevention of arterial and venous thromboembolic events (Ageno 
et al., 2012; Caudle et al., 2016). The understanding of the pharmacokinetics and 
pharmacodynamics of VKAs has been attributed to laboratory and clinical studies bringing to 
light interactions of VKAs, antithrombotic effects and the risks of using VKAs (Ageno et al., 2012). 
The basis of VKAs mechanisms of action is that they exert their thrombotic effect through 
interference with cyclic conversion of vitamin K and vitamin K epoxide (2, 3 epoxide) (Figure 1.1). 
As the VKAs have their antithrombotic effect, the gamma-carboxylation of the glutamate 
residues follows (Stafford, 2005; Ansell et al., 2008). In turn, gamma-carboxylation is needed by 
the vitamin k-dependent coagulation factors (II, VII, IX and X) to activate their coagulant activity 





































Figure 1.1: Coagulation cascade- The intrinsic and extrinsic pathway. The pathway of the activation of  
coagulation factors, adapted from (Davie, Fujikawa and Kisiel, 1991). 
 
 
Vitamin k antagonist treatment promotes the production of hepatic proteins that are partially 
carboxylated and decarboxylated with low coagulant activity (Friedman et al., 1977; Malhorta et 
al., 1985). A calcium-dependent conformational change in coagulation proteins requires 
carboxylation which leads to the binding of cofactors to phospholipid surfaces (Borowski et al., 
1986; Ageno et al., 2012). For carboxylation to occur, the reduced form of vitamin k, gamma-
carboxylase, carbon dioxide and molecular oxygen are required (Whitlon et al., 1978). An 
example of a vitamin k antagonist is warfarin. In addition to warfarin, there are several other 
anticoagulants including the new oral anticoagulants (NOACs) such as apixaban, rivaroxaban, 
dabigatran and edoxaban, however, our focus is on warfarin as it remains the most used 
anticoagulant world-wide (Fohner et al., 2015). 
 
1.2.1 New oral anticoagulants 
 
Warfarin is a primary vitamin k antagonist however; in recent years, four new oral anticoagulants 
(NOACs) have been introduced, targeting factors of the clotting cascade dabigatran, apixaban, 





observed in the use of NOACs. Though expensive, NOACs have been favoured by both patients 
and providers because they are easy to use and efficient (Barnes et al., 2015). It is for these 
reasons that they are used for stroke prophylaxis caused by atrial fibrillation (AF) and for treating 
and preventing venous thromboembolism (VT). However, there are still concerns about 
underutilization of NOACs (Ogilvie et al., 2010). With an estimated 3 million patients with AF and 
VT of whom 75 000 patients out of the 3 million patients are diagnosed annually. This indicates 
that the underutilization of NOACs may have clinical implications (Mozaffarian et al., 2015). 
Anticoagulant therapy for AF patients, to date, has not shown any improvements in 
underutilization of oral anticoagulants and this was observed through a nationwide analysis 
(Kirley et al., 2012; Mahan et al., 2012; Chugh et al., 2014; Patel et al., 2014). 
 
Table 1.1: Novel oral anticoagulants 
 
Drug Brand name Target Trial Reference 
     
Dabigatran Pradaxa® Factor IIa RE-LY (Connolly et al., 2009) 
     
Apixaban Eliqui® Factor Xa ARISTOTLE (Granger et al., 2011) 
     
Rivaroxaban Xarel® Factor Xa ROCKET AF (Patel et al., 2011) 
     
Edoxaban Lixiaa® Factor Xa ENGAGE AF-TIMI 48 (Giugliano et al., 2013) 




A process called contact activation activates factor XII to begin the process of coagulation (Renné 
and Gailani, 2007). Following the activation of factor XII, sequential activation of factor XI and IX 
proceed (Gailani and Renné, 2007). In the extrinsic pathway, activated plasma factor VII 
combines with tissue factor to initiate coagulation through injury (Mackman, 2004; Morrissey, 
2004). It is at level Xa where the intrinsic and extrinsic pathway unit activating thrombin to fibrin 
to complete coagulation. 
1.2.2 Warfarin use as an oral anticoagulant 
 
Warfarin, a vitamin k antagonist, was introduced in the 1950s and it has since become the 
most commonly used oral anticoagulant worldwide (Table 1.2) (Hirsh, 1992; Hirsh et al., 2001; 
Kornfield et al., 2012; Cho et al., 2016). It is a relatively inexpensive drug, however, through 
cost-analysis it has shown that the basis of warfarin dosage being monitored frequently makes 
the therapy more expensive (Anderson et al., 2002; Botteman et al., 2002; Stambler and 
Ngunga, 2015). For warfarin therapy, the primary aim of is to maintain a stable International 
normalised ratio (INR) with the lowest effective dose possible (Kuruvilla and Gurk-Turner, 
2001; Pirmohamed, 2013). In healthy people the ideal INR range is between 0.8-1.1. In general, 
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among patients on warfarin, the INR is expected between 2.0 to 3.5 (Hirsh et al., 2001; Kearon 
et al., 2008; Sonuga et al., 2016). The INR is a standardized measurement used to measure 
prothrombin (time taken for blood to clot) and serves as a crucial aspect of warfarin-related 
genetic studies. In addition, it enables the exchange and comparison of information between 
laboratories as well as different types of studies (Kamali and Wynne, 2010; Wells et al., 2014). 
The understanding of how INR works is important as it shows the correlation of variants with 
their phenotype with which genes (Eriksson and Wadelius, 2012; Lam and Cheung, 2012). 
International efforts have shown that the contribution of different variables include genetic 
variants among populations may cause trans-racial differences in warfarin dose requirements 
(Limdi et al., 2010; Wypasek et al., 2016). An international standard is used to test 
thromboplastin and this relationship is expressed as the International Sensitivity Index (ISI). 
INR is calculated as follows: 
 
 
INR = (patient prothrombin time/mean normal prothrombin time) ISI 
 
Table 1.2 Indicates warfarin prescriptions for different populations 
Population Year Warfarin Reference  
  prescriptions article  
US 2010 >30 million (Kirley et al., 
   2012)  
Canada 2013 5 million (Weitz et 
   al., 2015)  
Ireland 2010 57 000 (Health  
   Service  
   Executive,  
   2014)  
South Africa 2012 427 238 (Blaauw,  
   2012)  
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Warfarin is used for the prevention and treatment of thromboembolic complications linked with 
AF and thrombosis (Kuruvilla and Gurk-Turner, 2001; Kornfield et al., 2012). Treatment with 
warfarin is notably complicated and time consuming as it requires that an adequate dose is 
established for each individual specifically, and this is achieved by monitoring the anti-coagulant 
status using INR. Inter-individuality among warfarin patients is influenced by many factors 
including genetics (variations of the gene encoding the enzymes linked with the 
pharmacokinetics and pharmacodynamics of warfarin) and the non-genetic factors include race, 
age, height, body weight and diet (Rieder et al., 2005; Aquilante et al., 2006; Gage et al., 2008; 
International Warfarin Pharmacogenetics Consortium et al., 2009; Takeuchi et al., 2009; 
Yoshizawa et al., 2009; Johnson and Cavallari, 2013). Dosing algorithms have been developed 
because of the observation that genetic and non-genetic variables account for nearly 50% of the 
variance in warfarin dose (International Warfarin Pharmacogenetics Consortium et al., 2009; 
Johnson et al., 2011). Furthermore, proteins C and S which are naturally occurring endogenous 
anti-coagulant as well as clotting factors II, VII, IX and X are inhibited by warfarin (Horton and 
Bushwick, 1999; Njovane et al., 2013). 
 
The anticoagulant effect of warfarin has high implications on adverse drug reactions causing 
hospital admissions (Pirmohamed, 2013). One of those reactions include bleeding, with the risk 
being directly proportional with the intensity of anticoagulation as indicated by INR value (Hylek 
et al., 2007; Li et al., 2015). For instance, Pirmohamed et al. (2013) reported that an elderly 
population with an INR value >4.1 has a 25% risk of bleeding compared with those presenting 
with an INR between 2.0-3.0 (Pirmohamed et al., 2013). Consequently, administering fresh 
frozen plasma can reverse warfarin effect therefore limiting adverse reactions (Hanley, 2004). 
 
Adverse reactions such as haemorrhage in a US study by Hylek et al. (2007) have raised safety 
concerns about warfarin which has led to the discontinuation of the drug in the first year in 
about 26% of the elderly population (Hylek et al., 2007). It is for this reason that positive 
approaches have been implemented to improve anticoagulation control in warfarin patients and 
these include development of specialised anticoagulation clinics, initiating computerised dosing 
software programmes as well as dosing algorithms which help in obtaining accurate dosing. In 
addition, development of educational programmes for the patients (Rose, 2012) has had a huge 
positive effect. It has been found that patients appropriately trained in using a hand-held INR 
monitoring device to be able to monitor INR independently (Pirmohamed et al., 2013). 
Unfortunately, these measures have not been fully implemented in clinical practice (Pirmohamed 
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et al., 2013). However, patient self-management may be less expensive than anticoagulation 
clinic visits (Connock et al., 2007). 
 1.2.2.1 Warfarin resistance and warfarin sensitivity 
 
The inability to prolong the prothrombin time or raise INR to the optimal range when warfarin is 
administered at a normally prescribed dose is known as warfarin resistance (Lakshmi et al., 2012). A 
higher warfarin dose does not necessarily provide a diagnosis for warfarin resistance, in addition it is 
difficult to determine variation by patient population (Lakshmi et al., 2012). This difficulty is caused 
by dietary factors and establishing normal metabolic variations for individuals. A warfarin resistant 
patient is one that requires a dose of more than 105 mg per week which is equivalent to 15 mg/day. 
To reverse the effects of warfarin, warfarin resistant patients require lower doses of vitamin k 
(Thijssen, 1987; Hulse, 1996; Linder, 2001; Ansell et al., 2004). Warfarin resistance can be acquired or 
hereditary (Hulse, 1996; Vaes and Chyka, 2000). Acquired warfarin resistance is causes by difficulties 
in complying to warfarin therapy, increased consumption of vitamin k (Lakshmi et al., 2012), warfarin 
absorption decreased (Daly and Aithal, 2003), rapid warfarin clearance (Cain et al., 1997) and drug 
interactions (Vaes and Chyka, 2000; Wong and Chan, 2003). Hereditary warfarin resistance is thought 
to be caused by genetic factors that may either lead to enhanced metabolism of the drug 
(Pharmacokinetics) or reduced drug activity (Pharmacodynamics) (Lakshmi et al., 2012). 
Polymorphisms also have an influence, variants alleles in VKORC1 and CYP2C9 are associated with 
increased warfarin sensitivity (Lakshmi et al., 2012). 
 
1.2.2.2 Pharmacokinetics and pharmacodynamics of warfarin 
 
Warfarin interferes with vitamin k recycling in the liver, this affects vitamin k epoxide reductase 
complex (VKORC1) the main protein in vitamin k recycling (Li et al., 2004; Rost et al., 2004). This 
interference causes inactive vitamin k-dependent proteins to be secreted (Dahlbäck, 2005). 
Calumenin (CALU) inhibits the effects of warfarin by binding to vitamin k reductase (Wajih et al., 
2004). Other genes involved in vitamin k recycling is apolipoprotein E (APOE) and gamma 
glutamyl carboxylase (GGCX).  
 
Warfarin occurs as a stereoisomer of R- and S-enantiomers. The potency of S-warfarin is 3-5
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times more than the R-warfarin (Jaffer and Bragg, 2003; Ageno et al., 2012). Warfarin is a water-
soluble drug that has good bioavailability. It is absorbed from the gastrointestinal tract and it is 
able to reach maximum blood concentrations within 90 minutes after administration (Kelly and 
O’Malley, 1979). The half-life of racemic warfarin is 36 to 42 hours (S-enantiomer 29 hours, R-
warfarin 45 hours) (Jaffer and Bragg, 2003). Racemic warfarin is protein bound and accumulates 
in the liver where the S and R- warfarin are transformed metabolically by different pathways 
(Jaffer and Bragg, 2003). 
 
The S-warfarin is primarily metabolised by the cytochrome P450 2C9 enzyme which catalyses the 
reactions of 6-and 7-hydroxylation (Kunze and Trager, 1996), the predominate metabolite being 
(S)-7-hydroxywarfarin (Rettie et al., 1989) and minimally metabolised by CYP3A4 enzyme. In 
contrast, clearance of the R-warfarin forms 6-, 7-, 8- and 10-hydroxylated metabolites as well as 
alcohol reduction. Cytochrome P450 1A2 catalyses 6-hydroxylation, cytochrome P450 2C19 
catalyses 8-hydroxylation and cytochrome P450 3A4 catalysis 10-hydroxylation (Figure 1) (Kunze 
and Trager, 1996). Other genes involved in R-warfarin metabolism include CYP1A1, CYP2C8, 
CYP2C18, CYP2C19 and CYP3A5 (Rettie et al., 1992; Zhang et al., 1995; Kaminsky and Zhang, 
1997; Huang et al., 2004). For this study, we focussed on two genes namely; VKORC1 and GGCX. 
1.2.2.3 Common indications for warfarin anticoagulant use in Africa 
 
Of all anticoagulants, warfarin remains the most effective for the treatment and prevention of a 
variety of prothrombotic cardiovascular, stroke and hematologic conditions (Petersen et al., 
1989; Hart et al., 2007) and it is for this reason that it has been used for over 60 years (Avorn, 
2011; Friberg et al., 2012). Warfarin usage is commonly for the treatment and/or prevention of 
atrial fibrillation, pulmonary embolism, mechanical valve replacement and deep vein thrombosis 
(Lee and Klein, 2013). 
 
Atrial fibrillation, a common cardiac arrhythmia, cases in the developed world has a high 
expected prevalence than in Africa because of the increased aging population observed in this 
region (Fuster et al., 2011). Furthermore, Africa has a high incidence of under treatment of 
streptococcal infections which contribute to the increased burden of valvular AF in relation to 
rheumatic disease (Damasceno et al., 2012; Bloomfield et al., 2013). The high incidence is 
thought to be attributed to limited skilled staff and minimum public awareness about diagnosis, 
poor access to primary healthcare and quick treatment of suspected streptococcal infections. In 
a country like South Africa, a primary public health prevention strategy should minimise costly 
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diagnostic testing, be cautious of missed diagnosis and reduce unnecessary antibiotic treatment 
(Kromberg and Krause, 2013). Between 1990 and 2010, AF was the highest cardiovascular 
disease burden in sub-Saharan African (SSA) (Moran et al., 2013). By 2050, the prevalence of AF 
is estimated to be higher in Africa than other continents (Rahman et al., 2014). Furthermore, the 
prevalence of stroke as a result of AF is high and stroke resulting from AF is more disabling with a 
high mortality risk than stroke from other causes (Lin et al., 1996; Camm et al., 2010; Hannon et 
al., 2010). 
 
A hospital-based South African study reported that 4.6% of cardiology patients had AF, 
suggesting a 5.6% prevalence of cases per 100 000 populations per year (Sliwa et al., 2010). In 
addition, there was a 5.5% prevalence of AF for patients admitted over a 10-year period in a 
cardiology institute in Ivory Coast (Coulibaly et al., 2010). Similarly, Mbaye et al. (2010) on a 
Senegalese retrospective study, reported the prevalence of AF to be 5.4% with AF causing 66% 
cardiac disorders (Mbaye et al., 2010). However, Shavadia et al. (2013) in Kenya, reported only 
0.7% prevalence rate of AF (Shavadia et al., 2013). Notably, the low rates of AF reported for 
African populations may not be a true reflection of the disease burden. These low rates may be 
as a result of care seeking behaviour and most importantly, the fact that access to health care 
facilities is a challenge in Africa (Stambler and Ngunga, 2015) and that most studies are only 
focussed on a few if not one hospital. 
 
Globally, stroke is the second most common cause of death (Murray and Lopez, 1997; Stambler 
and Ngunga, 2015) with nearly 70% of these deaths occurring in developing countries especially 
in Africa (Connor et al., 2005). Stroke was the leading cause of disability and death in 2010 within 
Africa (Moran et al., 2013). Therefore, the knowledge of warfarin dose is important as it is used 
to prevent stroke (Connor et al., 2005). It is estimated that more females die from stroke than 
males (Connor et al., 2005). However, there is still a high rate of general anticoagulant morbidity 
and mortality. The knowledge of genetic and non-genetic variables is of interest because of the 
wide inter-individual differences and the low therapeutic index of warfarin that influences the 
dose requirements for warfarin (Cooper et al., 2008; Takeuchi et al., 2009; Kamali and Wynne, 
2010; Skov et al., 2012). 
1.2.2.4 Burden of stroke and atrial fibrillation and use of warfarin 
 
The prevalence of stroke was 1.63/1 000 and 1.14/1 000 in rural and urban Nigeria, respectively 
(Danesi et al., 2007; Oldgren et al., 2014). On the contrary, the prevalence of stroke in African 
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Americans was 3.8% in 2012 (Go et al., 2014). In Ethiopia, a single-centred study reported the 
mean age of stroke patients was 53.2 years and mortality was 44.5% (Zenebe et al., 2005). The 
annual incidence of stroke in South Africa is approximately 75 000 (Bertram et al., 2012). Jowi 
and Mativo. (2008) reported on a Kenyan cohort that the mean age was 61 years and 40% of 
these patients had valvular heart disease with half also having not received any form of 
treatment (Jowi and Mativo, 2008). Treatment can be in the form of well managed 
anticoagulation control which enables warfarin to reduce the risk of stroke in AF patients 
through the maintenance of INR for at least 60-70% of the time (Connolly et al., 2008; Morgan et 
al., 2009). At the same time, warfarin therapy has a risk of haemorrhage and the effectiveness of 
warfarin can be reduced through the administration of vitamin k. Warfarin, however, has a 
longer mechanism of action than vitamin k thus re-administration of vitamin k is required for 
patients with ongoing bleeding complications (DeZee et al., 2006). Complications in patient 
treatment results in significant costs for the patient (Bramkamp, 2006). Atrial fibrillation costs 
include anticoagulation cost, treatment of stroke associated with AF and INR monitoring 
(Stambler and Ngunga, 2015). 
 
1.3 Inter-individual variability in response to warfarin 
 
During the initiation phase, daily monitoring of INR is recommended because it is difficult to 
predict initial individual doses (Pirmohamed et al., 2013). An INR range between 2.0-3.0 is 
recommended for most disease indications while cardiac valve procedures recommend a INR 
range between 2.0-3.5 (Hirsh et al., 2001; Kearon et al., 2008; Sonuga et al., 2016). The 
maintenance of warfarin dose is essential. Warfarin has a narrow therapeutic range for INR 
therefore, sub therapeutic INR caused by under dosing results in thrombosis and supra 
therapeutic INR causes excessive haemorrhage (Natarajan et al., 2013) leading to dose 
variability. 
 
Warfarin response is associated with a high inter-individual dose variability to achieve INR, which 
is affected by demographic variables such as age, BMI, clinical factors and genetic variation in 
genes. The most commonly studied genes are CYP2C9, and vitamin k epoxide reductase complex 
subunit 1 coding gene, VKORC1 (Caldwell et al., 2007; Yang et al., 2013). Other factors that cause 
INR fluctuations include concomitant illnesses, drug interactions, vitamin k intake, inaccurate 




1.3.1 Concomitant illness 
 
The anticoagulant response of a patient is affected by various drugs and diseases (Demirkan et 
al., 2000; Ageno et al., 2012). Firstly, Howard-Thompson et al. (2014) recommend that patients 
with thyroid dysfunction be monitored carefully (Howard-Thompson et al., 2014). They suspect 
that the catabolism of vitamin k-dependent clotting factors is decreased by hypothyroidism 
consequently decreasing the response to warfarin. They further observed a general trend of 
increase in warfarin dose with a decreasing INR (Howard-Thompson et al., 2014). In contrast, the 
catabolism of vitamin k-dependent clotting factors is increased in hyperthyroidism with a general 
trend of decreased warfarin with an increased INR (Jaffer and Bragg, 2003). 
 
Secondly, non-renal drug clearance and metabolism has generated increased attention on the 
potential effect on chronic kidney disease (CKD). These patients are at a risk of acquiring 
cardiovascular disease, bone disease and anaemia. Consequently, they require multiple drugs for 
treatments of these conditions (Anderson et al., 2009; Knauf and Aronson, 2009; Weiner and 
Rifkin, 2009). Increased coagulation factors such as factor VIII, fibrogen and von Willebrand cause 
prothrombic events in CKD patients (Wattanakit and Cushman, 2009; Pavord and Myers, 2011; 
Lutz et al., 2014). Expectedly, dose alterations are necessary for patients with CKD on drugs that 
primarily use renal excretion like warfarin (Limdi et al., 2010). 
 
Within warfarin initiation therapy, it is estimated that about 20.5% of patients experience a 
minimum of one episode of warfarin related nephropathy (Brodsky et al., 2011; An et al., 2013). 
Clinicians have acknowledged that it is more challenging to manage anticoagulation in patients 
with kidney impairment and that it is unfortunate that both kidney impairment patients as well 
as the general medical population receive similar initiation doses and are managed similarly 
(Elliott et al., 2007; Genovesi et al., 2008; Brodsky et al., 2011; An et al., 2013). It has been 
reported that assessing warfarin dose requirements is necessary for patients with CKD. These 
patients require lower warfarin maintenance doses, and if the disease is severe, anticoagulation 
control is impaired (Limdi et al., 2009, 2010). Over-anticoagulation and under-anticoagulation are 
at an increased rate and major haemorrhage which is caused by over-anticoagulation is at a two-
fold increased risk in CKD patients (Dreisbach et al., 2003; Elliott et al., 2007). These results were 
obtained from studies that assessed haemorrhage risk in dialysis patients undergoing warfarin 




In a Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, no significant 
differences were observed in acute kidney injury (AKI) between warfarin and dabigatran use 
(Shafi et al., 2013; Escoli et al., 2015). Interesting to note that in a post hoc analysis of RE-LY, AF 
dabigatran patients indicated a slower reduction in renal function than warfarin patients and the 
reduction of renal function was increased because of previous warfarin exposure and if the 
patient was diabetic (Böhm et al., 2015). Nonetheless, it is still unclear about the impact of 
dabigatran and warfarin use in association with AKI in real-world clinical practice (Zhangi et al., 
2016). 
 
There is limited clinical knowledge on the effect of liver disease on warfarin therapy available. 
Clinicians do not know whether liver disease treatment together with warfarin treatment may 
have successful anticoagulation control or increase bleeding risk (Efird et al., 2014). With the 
recent developments of direct oral anticoagulants, liver disease patients were excluded from the 
trials (Connolly et al., 2009; Schulman et al., 2009; Granger et al., 2011; Patel et al., 2011). As a 
result, there is currently no planned or existing trial that may assist with the management of liver 
disease patients requiring anticoagulation therapy (Efird et al., 2014). 
 
In anticoagulation, the imbalanced state of pro- and anticoagulants has been described as 
advanced liver disease and it is distinguished by hematologic abnormalities (Tripodi and 
Mannucci, 2011). Hindered clotting factor levels in synthetic liver damage may extend 
prothrombin time (Villa and Maria, 2012). In addition, patients with chronic liver disease are 
likely to have reduced serum albumin (liver protein), this is believed to be due to structural 
alterations in the molecule. Consequently, reducing binding ability and distribution in the body 
(Ivanov et al., 2002). Furthermore, liver disease patients are at an increased risk of 
thromboembolism (Søgaard et al., 2009; Efird et al., 2014). The reduction of activity in protein C-
induced inhibition is thought to affect the prothrombotic state (Tripodi and Mannucci, 2011). 
 
The uncertainties on whether to seek anticoagulation therapy for liver disease patients still 
remains unresolved (Efird et al., 2014). Patients with stable mild to moderate liver disease 
indicating anticoagulation are likely to be in a balanced state of anticoagulant factors and, 
therefore, the risk of anticoagulation is reduced. However, those with severe liver disease are 
poor candidates (Efird et al., 2014). For these patients, it would be beneficial if clinicians
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would consider the risks and benefits of using warfarin. Unfortunately, currently there are no 
models that can assist the clinicians with the identification of patients that can be on warfarin 
therapy without experiencing complications (Efird et al., 2014) likely due to drug interactions. 
 
1.4 Warfarin use and Drug interactions 
 
Drug interactions are the most common cause of INR fluctuations which increase the risk of 
haemorrhage or coagulation. These interactions may be defined as pharmacokinetic (PK) or 
pharmacodynamic (PD) (Jaffer and Bragg, 2003). PK interactions affect drug absorption, protein 
binding and warfarin hepatic metabolism (for example cholestyramine affects warfarin 
absorption) (Jähnchen et al., 1978; Jaffer and Bragg, 2003). In addition, Valproic acid and non-
steroidal anti-inflammatory drugs (NSAIDs) change the binding of plasma protein to warfarin 
(Sands et al., 2002). Some NSAIDs that have antiplatelet activity enhance the anticoagulation 
effect when administered together with warfarin (Knijff-Dutmer et al., 2003). In contrast, PD 
interactions affect haemorrhage or coagulation through effects of antiplatelet or alterations in 
vitamin k catabolism (Jaffer and Bragg, 2003). 
 
1.4.1 Vitamin k intake 
 
A diet consisting of high levels of vitamin k consumption results in the increase of vitamin k 
clotting factors which consequently decrease the anticoagulant response to warfarin (Booth et 
al., 1997). Thus, low vitamin k consumption leads to an increased anticoagulant response to 
warfarin (Jaffer and Bragg, 2003). It is therefore important to have a consistent vitamin k intake 
to afford accurate warfarin dosing (Darnell et al., 2014). In a single serving, food that is highly 
concentrated with vitamin k is the green leafy vegetables such as turnip greens, spinach and 
broccoli (Booth and Centurelli, 1999). Unfortunately, patients are misinformed and have been 
advised to avoid such types of foods which are nutritious. Patients should be advised if they want 
to eat these types of foods to do so in moderation (Jaffer and Bragg, 2003). A healthy diet may 
include these types of foods (Jaffer and Bragg, 2003). However, environmental factors should not 





1.5 Environmental factors affecting warfarin metabolism 
1.5.1 Alcohol 
 
Alcohol use is among the strongest risk factors for major bleeding for individuals using warfarin 
(Efird et al., 2013). For instance, warfarin patients are advised to use alcohol infrequently by 
American Heart Association, however, no specific evidence is cited (Hirsh et al., 2003). For 
patients with genetic variants that affect the anticoagulation cascade and warfarin metabolism, 
alcohol use could have problematic implications for warfarin safety and consequently affecting 
dose requirements (Limdi et al., 2008; McDonald et al., 2009; Roth et al., 2014). This particularly 
affects patients with genotypes that suggest lower warfarin dose requirements, to reach 
therapeutic anti-coagulation levels, to a higher risk of bleeding if the genetic status is not known 
(Roth et al., 2015). 
 
The exact mechanism is not clear in literature, this can include compromised hepatic metabolism 
and other patient-specific factors (Noureldin et al., 2010). Roth et al. (2015) observed that 
patients with lower hepatic vitamin k reductase complex (VKORC) content as well as reduced 
warfarin clearance to be more likely to experience biochemical changes carried out by alcohol 
than patients who have a faster hepatic metabolism and do not have this genetic mutation (Roth 
et al., 2015). Alcohol consumption increases warfarin metabolism, this reduces warfarin efficacy 
leading to an increased risk of clot formation. Contrary, acute alcohol consumption may also 





Components of tobacco smoke induce CYP1A2 (R-warfarin is a substrate of CYP1A2) which is 
attributed to interaction of warfarin with smoking (Kroon, 2007). This interaction in humans 
causes increased risk of thrombotic events (Kroon, 2007; Angoulvant et al., 2015). Warfarin 
clearance has been reported to be enhanced by smoking thereby suggesting the requirement of 
dose adjustments (Sohn et al., 2015). On the contrary, no differences were observed in warfarin 
dose requirements for previous smokers or current smokers in a retrospective study (Whitley et 
al., 2007). Angoulvant et al. (2015) reported that atrial fibrillation patients who smoke may be 
exposed to an increased risk of thromboembolic events and/or an increased risk of bleeding 
(Angoulvant et al., 2015). However, there are minimum guidelines available on smoke 
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termination and the management of anticoagulation therapy (Reichert et al., 2008; Nathisuwan 




Warfarin use is discouraged in pregnancy because it leads to foetal warfarin syndrome (FWS), a 
congenital abnormality that is caused by warfarin passing through the placenta because of its low 
molecular weight (Hall et al., 1980; Yurdakök, 2012). Warfarin sensitivity in pregnancy is greatest 
between week 6 and 9 of gestation (Hall et al., 1980; Bian et al., 2012). Common features of FWS 
included skeletal abnormalities, nasal hypoplasia and stippled epiphyses (Kumar et al., 2012). 
Furthermore, interference in the activity of the vitamin k reductase causes a depletion in the levels of 
vitamin k mineralization inhibitors osteocalcin and matrix gla protein in cartilages resulting in 
displaced calcium deposits in epiphysis. Foetal complications are thought to be associated with 
warfarin dose requirements (Basu et al., 2016). Khamooshi et al. (2007) reported embryopathy and 
foetal loss occurring when warfarin administration is above 5 mg (Khamooshi et al., 2007). The 
continuation of warfarin until late gestation can cause haemorrhages in foetal organs leading to 
mortality (Menger et al., 1997; Hassouna and Allam, 2014). Other anomalies associated with FWS 
include microcephaly, short neck, upper airway obstruction, choanal atresia, growth retardation, 
laryngeal abnormalities, blindness, optical atrophy, deafness, telebrachydactyly, pectus carinatum, 
congenital heart defects, seizure, mental retardation, hydrocephalus, Dandy Walker malformation 
and agenesis of corpus callosum (Hall et al., 1980; Hou, 2004; Mazibuko et al., 2012). 
 
1.6 Genetics of warfarin 
 
Warfarin metabolism is affected by genetic polymorphisms in CYP2C9 and VKORC1 both of which 
account for 30%-40% of warfarin dose variation (Bodin et al., 2005; Sconce et al., 2005; Vecsler et al., 
2006). Genetic studies have identified genetic variants and other candidate genes which are 
associated with dose requirements. These genes include gamma-glutamyl carboxylase (GGCX), 
epoxide hydrolase 1 (EPHX1), calumenin (CALU) and CYP2C19 (Wadelius et al., 2007; Luxembourg et 
al., 2010; Huang et al., 2011). Figure 1.2 shows S and R- warfarin metabolism with some of the genes 
involved in the PK and PD of warfarin. For this study, we investigated polymorphisms in two genes: 

























Figure 1.2: S- and R-warfarin metabolism in the vitamin k cycle. S-warfarin mainly metabolised by CYP2C9 enzyme 
to 7-Hydroxywarfarin. R-warfarin mainly metabolised by CYP1A2 and CYP3A4 to 6-, 8-, 10- Hydroxywarfarin. 
Warfarin inhibits VKOR as indicated by the red cross therefore preventing the activation of clotting factors, adapted 
from (Tie et al., 2011). 
 
1.6.1 Cytochrome P450 2C9 (CYP2C9) 
 
CYP2C9 is located on chromosome 10q24 (Ansell et al., 2008) and is the main enzyme responsible for 
S-warfarin metabolism (Van Booven et al., 2010) contributing 10% of dose variation in warfarin 
patients (Verhoef et al., 2014). In addition, genetic variation in CYP2C9 causes changes in enzyme 
activity leading to compromised metabolism (Van Booven et al., 2010). Decreased CYP2C9 due to 
polymorphisms results in increased concentrations of warfarin which are associated with increased 
bleeding. Literature has extensively investigated two non-synonymous single nucleotide 
polymorphisms (SNPs) within CYP2C9 (CYP2C9*2 - rs1799853 and CYP2C9*3 - rs1057910) mostly 
among Caucasian and Asian populations (Yasar et al., 1999; Yoon et al., 2001; Burian et al., 2002; 
Yildirim et al., 2014). These SNPs have showed a strong association with warfarin response variability. 

















Table 1.3: Allele frequency for CYP2C9*2 &*3 among different populations 
 
Geographical Racial 
CYP2C9*2 CYP2C9*3 Reference 
population population    
Mozambican African 0 0.01 (Vargens et al., 2011) 




(Dandara  et  al.,  2011; 
 Mitchell et al., 2011)     
     
Egyptian 
African/Asian 
0.117 0.092 (Shahin et al., 2011)  
     
Omani Asian 0.074 0.029 (Tanira et al., 2007) 
 
     
Chinese Asian 0.01 0.02 (Yuan et al., 2005) 
 
     
Turkish Caucasian/Asian 0.13 0.1 (Ozgon et al. 2008) 
     
African Caucasian 
0.01 0.01 (Wu et al., 2008) 
American      
British Caucasian 0.14 0.085 (Sconce et al. 2005) 
     
 
 
1.6.2 Vitamin k epoxide reductase complex 1 (VKORC1) 
 
Warfarin resistance and clotting factor deficiencies are caused by variations found in the gene 
targeted by warfarin, VKORC1 an enzyme located on chromosome 16, regulates the recycling of 
vitamin k 2,3 epoxide to vitamin k hydroquinone (Li et al., 2004; Rost et al., 2004; Natarajan et 
al., 2013). With the inhibition of VKORC1, there is a blockage in the production of vitamin k which 
limits the availability of vitamin k epoxide in the liver consequently leading to pro-coagulation 
factors that are non-functional (Militaru et al., 2015). Polymorphisms in VKORC1 contribute 30% 
to warfarin dose requirements (Rost et al., 2004). These include: -1639G>A (rs9923231), 1173C>T 
(rs9934438), 1542G>C (rs8050894), 2255C>T (rs2359612) and 3730G>A (rs7294) (Dean, 2012) 
(Table 1.4). There have been several studies that have examined the association of the -1639G>A 
(rs9923231) polymorphism found in the promotor region of VKORC1 with warfarin dosing 
variability (Harrington et al., 2004; Kimura et al., 2007; Wu et al., 2008; Sconce. et al., 2009; 


















Table 1.4: Indicates allele frequency distribution of VKORC1 SNPs among different populations 
 
Population c.-1639A c.1173T c.1542C c.2255T c.3730A Reference   
Mozambican 0.035 N/A 0.273 N/A 0.389 
(Suarez-Kurtz et al., 
2010)           
       
South African N/A 0.04 N/A 0.24 0.40 (Dandara et al., 2011) 
         
Angolan 0.027 N/A 0.192 N/A 0.404 
(Suarez-Kurtz et al., 
2010)           
         
Brazilian 0.211 N/A 0.344 N/A 0.469 
(Suarez-Kurtz et al., 
2010)           
         
African 




         
 
 
The VKORC1 c.-1639G>A polymorphism changes the binding site for VKORC1 promotor region, 
this results in lower VKORC1 mRNA expression in the liver. Consequently, the concentration of 
tissue VKOR is lowered making a person with this variation more likely to inhibition by warfarin 
and also causing warfarin sensitivity (Gage et al., 2008; Linder et al., 2009). VKORC1 rs9934438 
(c.1173C>T) as well as rs7294 (c.3730G>A) (synonymous variant) are associated with warfarin 
dose variability (D’Andrea et al., 2005). 
 
1.6.3 Gamma-glutamyl carboxylase (GGCX) 
 
The GGCX gene encodes the GGCX enzyme. It is located on chromosome 2p11.2 on the reverse 
strand (De Vilder et al., 2017). The vitamin k cycles controls anticoagulation through the gamma-
carboxylation of glutamic acid residues which are on the vitamin k-dependent factors (factor II, 
VII, IX, X, Protein S and Protein C) (Hirsh et al., 2001). The carboxylation process is carried out by 
GGCX (Presnell and Stafford, 2002). GGCX together with vitamin k hydroquinone (K1H2) as a 
cofactor facilitate the carboxylation process and VKORC1 recycles it back to K1H2 (Rieder et al., 
2007). 
 
Brenner et al. (1998) reported mutations in GGCX in four patients with a deficiency in all Vitamin 
K Dependent Clotting Factors (VKDCF) type 1 (Brenner et al., 1998). These mutations were 
caused by homozygous missense mutation in the gene (Brenner et al., 1998; Rost et al., 2004; 
Rost et al., 2006). In addition, vitamin k cycle has an important role on haemostasis regulation 
and the presence of non-synonymous mutations in VKORC1 lead to VKDCF type 2 (Rost et al., 
2004). Mutations in GGCX and VKORC1 has drastic effects on clotting factor production, this 
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highlights the hypothesis that there are subtle regulatory polymorphisms in these genes that 
affect vitamin k cycling (Bodin et al., 2005; Wang et al., 2008) thereby affecting warfarin therapy. 
1.7 Study rationale 
 
Compared to European and Asian populations, African populations remain poorly studied with 
respect to the pharmacogenetics of warfarin. It is however known that African populations do 
not always possess the same genetic profiles as Caucasian or Asian populations thus the dosing 
algorithms that are currently available do not cater for African populations. Huge differences 
have been observed among African populations in dosage requirements to reach INR as well as 
variations in time required to reach INR. 
 
Warfarin is extensively used among patients and may remain so for a long time to come. A study 
by Anakwue et al. (2014), reported that there are no optimum available anticoagulation service 
centres which provide targeted and desired outcomes in Nigeria (Anakwue et al., 2014). The 
current available anticoagulation centres are managed by haematologists of which there are not 
that many. There are only two African countries that have monitoring clinics in their 
anticoagulation centres, namely; South Africa and Kenya (Anakwue et al., 2014). The South 
African Anticoagulation clinics (ACCs) are managed by physicians, doctors and nurses (Jacobson 
et al., 2009), whereas in Kenya, these clinics are managed by pharmacists (Anakwue et al., 2014). 
Other African countries such as Nigeria which do not have adequate ACCs can adapt the South 
African thrombo-embolism prophylactic and treatment guidelines to assist in their plans of 
achieving anticoagulation practices (Jacobson et al., 2009). Despite the availability of these 
clinics, the desired anticoagulation remains low in Africa, ranging from 7% to 30% in Kenya, 
which is comparable to the study by Anakwu et al. (2014) in Nigeria (Anakwue et al., 2014). 
While South Africa ranges between 32% to 58% (Tiryaki et al., 2011). 
1.7.1 Justification 
 
Genomics is gaining momentum in explaining some of the observed differences in drug 
responses, including response to warfarin. We carried out pharmacogenomics research to 
identify genetic markers associated with dose requirements among African populations and 
those of mixed ancestry origin. We were interested in investigating the contribution of genomic 
variation on warfarin pharmacokinetics (PK) and pharmacodynamics (PD).
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The candidate PK and PD genes were VKORC1 and GGCX, respectively. We had also characterised 
two other genes; CYP2C9 and CYP4F2 however, the SNPs for these genes were not validated 
therefore excluded from the analysis of the current study. We therefore hope that the genetic 
markers identified in this study may be used by clinicians to develop personalized pharmaco-
therapeutic regimes for their patients. This may reduce the possibility of harmful side-effects and 
inadequate drug responses (Arvanitidis et al., 2007). 
1.7.2 Study aim 
 
The primary aim was to investigate the correlation between warfarin dose and genotypes for 
VKORC1 and GGCX. 
 
This was approached through these objectives: 
 
• Identification and recruitment of patients using warfarin at INR clinics in Cape Town, South 
Africa 
 
• Characterization of known candidate single nucleotide polymorphisms (SNPs) from previous 
literature: VKORC1 c.-1639G>A, VKORC1 c.1173C>T, VKORC1 c.3730C>T, GGCX c.1218C>T and 
GGCX c.1242C>T 
 
• Determination of allele and genotype frequencies of the study cohort 
 






































Chapter 2: Methods and Materials 
 
2.1 Patient recruitment 
 
2.1.1 Study site and patient recruitment 
 
This study was conducted at the University of Cape Town, Medical School. Consenting patients 
were recruited from Groote Schuur Hospital (GSH) and Gugulethu Community Health Centre 
(GCHC) clinics. Ethical clearance was obtained from the University of Cape Town, Human 
Research Ethics Committee (HREC) REC REF: 581/2015. We recruited in two locations because we 
saw that in GSH the frequent population group visiting the clinic was the Mixed Ancestry. The 
patients consented to access to their demographic data and clinical information and 5 ml of 
blood for genetic characterisation was collected in ethylenediaminetetraacetic acid (EDTA) 
coated tubes.  
 
2.1.2 Inclusion and exclusion Criteria 
 
This study included both male and female patients above the age of 18 years who were already 
on warfarin therapy. The patients had any of the following conditions: atrial fibrillation (AF), deep 
vein thrombosis (DVT), pulmonary embolism (PE) and prosthetic/ mechanical valve replacement. 
A total of 372 patients were included in the genetic analysis. Patients that were excluded were 
those that were haemophilic as they already have a blood condition, vulnerable or not in a good 
mental condition, pregnant and those under 18 years. 
 
2.2 DNA extraction and Genetic characterisation 
 
To carry out genetic characterisation, blood was used to extract DNA which was then kept at -
20°C until needed for analysis. Genomic DNA was extracted using a modified version of 
Gustafson et al. (1987) method (Gustafson et al., 1987). Blood samples were left at room 
temperature to thaw before proceeding with DNA extraction. Samples were then transferred to 
10 ml tubes and phosphate-buffered saline (PBS) was added up to 10 ml. The tubes were mixed 
by inverting the tubes and centrifuged at 2500g for 15 minutes. A reddish pellet was visible after 




The pellet was re-suspended in 10 ml of Sucrose Triton X-100 lysing buffer and vortexed before 
centrifugation at 2500g for 15 minutes. The supernatant was poured out carefully, with a 
pinkish/white pellet visible. The pinkish/white pellet was re-suspended in 3 ml T20E5, with 200 
ml. 10% sodium dodecyl sulphate (SDS) and 37.5 µl Proteinase K added, however, mixed by 
inversion after adding each solution. The samples were incubated in a water bath at 45°C 
overnight. The following day, 1 ml of saturated sodium chloride (NaCl) was added and mixed 
vigorously for 15 seconds then span for 30 minutes at 2500g, a white pellet was visible which 
consists of protein precipitated by salt. At this point, the DNA is found in the supernatant thus 
the supernatant was transferred into a new tube. For precipitation of the DNA, 2 volumes of 
absolute alcohol were added and kept at room temperature at least 30 minutes. The samples 
were mixed vigorously and centrifuged for 10 minutes at 2500g and the supernatant discarded. 
At this point, the DNA is expected to settle at the bottom of the tube and 70% alcohol is used to 
wash the DNA. Samples were left to air dry for 4 hours. After 4 hours, an appropriate volume 
(100-250 µl) Tris EDTA (TE) was added to dissolve the DNA and left for 3 days to dissolve the DNA 
at 4°C. After the 3 days, the absorbance at 260 and 280 nm was measured. 
 
After DNA extraction, the integrity of the DNA was checked using a (w/v) 1% agarose gel 
(SeaKem LE Agarose, Lonza, Maine, USA) against a 100 base pair (bp) molecular marker (Thermo 
Fischer Scientific, Massachusetts, USA) as a reference for size. Samples were visualised using the 
UviTec Cambridge UV visualizer (Whitehead Scientific, MA, USA). For genetic characterisation 
SNPs selected were chosen based on the minor allele frequency of other African populations or 
African Americans. 
 
2.2.1. Primer selection 
Genetic characterisation was achieved using restriction fragment length polymorphism and 
Sanger sequencing method. Table 2.1 shows SNP significance and sequences of primers used. 








Table 2.1: SNP primers and expected fragment sizes after digestion 
 
    PCR   
SNP SNP Primers Method product Reference 
 significance   size   
    (bp)   
VKORC1 Decrease F:  
291/ 
(Natarajan 
c.- RNA GAGCCAGCAGGAGAGGGAAATAT PCR/RFLP et al., 
Msp I 




   
VKORC1 





PCR/RFLP et al., 
c.1173C>T R: TGACATGGAATCCTGACGTG Hinf I 
expression  2010)       
  
F: AGCCTGATGTGGCTCAGTTT 




 design-  
protein 262 Primer  
c.3730G>A R: GTGTGGCACATTTGGTCCATT sequencing 
 
expression  Quest  
     Tool  









c.1218C>T R: sequencing  
 expression CTTGAGAAAAGGCAAAGCAGAC   Quest      Tool        









c.1242C>T R: sequencing  
  CTTGAGAAAAGGCAAAGCAGAC   Quest      Tool         




2.2.1.1 PCR reactions and conditions 
 
The VKORC1 gene is located on the short arm of chromosome 16 at position 11.2. It consists 
of three exons (Figure 2.1) and encodes 163 amino acids. Discussed below is the PCR 





















In a total reaction of 25 µl; 1X Green GoTaq PCR buffer (Promega, Madison, WI, USA), 3 mM of 
MgCl2 (Promega, Madison, WI, USA), 0.2 mM Deoxynucleotide Triphosphates (dNTPs) (Celtic 
Molecular Diagnostics, Cape Town, SA), 0.32 µM of each primer (Integrated DNA Technologies, 
Illinois, USA), 1 unit Go-Taq (Promega, Madison, WI, USA), the reaction mix was topped up to 25 
µl using sabax deionised water (Adcock Ingram, Johannesburg, SA) and 100 ng of genomic DNA 
was used as a template in the PCR reaction. The thermal cycling T100™ Thermal Cycler (Bio-Rad 
Laboratories, California, USA) was used for DNA amplification. The cycling conditions were as 
follows: initial denaturation at 94°C for 10 minutes, 94°C denaturation for 1 minute, 66°C 
annealing for 1 minute, 72°C extension for 1 minute, a total of 35 cycles were included, total 
extension at 72°C for 10 minutes. Samples were visualised on a (w/v) 1% agarose gel (SeaKem LE 
Agarose, Lonza, Maine, USA) and a 100 bp molecular marker (Thermo Fischer Scientific, 
Massachusetts, USA) used as a reference. 20 µl/100ml of 1X E-Z Vision gel nucleic acid stain 
(Thermo Fischer Scientific, Massachusetts, USA) was added for staining. PCR product size was 
361 bp. The gel ran at 100 V for 45 minutes. 
 
To digest the 291 bp amplicon, 3 µl of 10X CutSmart Buffer (New England Biolabs, 
Massachusetts, USA), 10 units MsPI was added to 10 µl PCR product. The reaction was topped up 
to 30 µl with sabax deionised water (Adcock Ingram, Johannesburg, SA). The digestion reaction 
was conducted at 37°C for an hour. A 3% agarose gel was used to separate the fragments which 
was stained with 1X E-Z Vision gel nucleic acid stain (Thermo Fischer Scientific, Massachusetts, 
USA). The restriction sequence identified by MsPI is C^CGG (Figure 2.2). Wild type c.-1639GG 
yielded two fragments 124 bp and 167 bp, the homozygous c.-1639AA yielded a single 




















































Figure 2.2: Amplified region containing VKORC1 c.-1639G>A. Forward and reverse primer highlighted in green with 
the direction indicated by the arrows. Sequence highlighted in blue is the restriction recognition site with the red letters 




In a total reaction of 25 µl; 1X Green GoTaq PCR buffer (Promega, Madison, WI, USA), 3 mM of 
MgCl2 (Promega, Madison, WI, USA), 0.2 mM Deoxynucleotide Triphosphates (dNTPs) (Celtic 
Molecular Diagnostics, Cape Town, SA), 0.4 µM of each primer (Integrated DNA Technologies, 
Illinois, USA), 1 unit Go-Taq (Promega, Madison, WI, USA), the reaction mix was topped up to 25 
µl using sabax deionised water (Adcock Ingram, Johannesburg, SA) and 100 ng of genomic DNA 
was used as a template in the PCR reaction. The thermal cycling T100™ Thermal Cycler (Bio-Rad 
Laboratories, California, USA) was used for DNA amplification. 
 
The conditions for PCR cycle were as follows: initial denaturation at 94°C for 10 minutes, 94°C 
denaturation for 1 minute, 56°C annealing for 1 minute, 72°C extension for 1 minute, a total of 
35 cycles were included, total extension at 72°C for 10 minutes. Samples were visualised on a 
(w/v) 1% agarose gel (SeaKem LE Agarose, Lonza, Maine, USA) and a 100 bp molecular marker 
(Thermo Fischer Scientific, Massachusetts, USA) used as a reference. 20 µl/100ml of 1X E-Z Vision 
gel nucleic acid stain (Thermo Fischer Scientific, Massachusetts, USA) was added for staining. PCR 
product size was 361 bp. The gel ran at 100 V for 45 minutes. To digest the 361 bp amplicon,
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3 µl of 10X CutSmart Buffer (New England Biolabs, Massachusetts, USA), 10 units HinfI was added 
to 10 µl PCR product. The reaction was topped up to 30 µl with sabax deionised water (Adcock 
Ingram, Johannesburg, SA). The digestion reaction was conducted at 37°C for an hour. Fragments 
were separated on a 3% agarose gel stained with 1X E-Z Vision gel nucleic acid stain (Thermo 
Fischer Scientific, Massachusetts, USA). The restriction sequence identified by HinfI is G^ANTC 
(Figure 2.3). Wild type c.1173CC yielded two fragments 8 bp and 353 bp fragment, the 
homozygous c.1173TT yielded three fragments 8 bp, 43 bp and 310 bp, and the heterozygous 


























Figure 2.3: Amplified region containing VKORC1 c.1173C>T. Forward and reverse primer highlighted in green with the 
direction indicated by the arrows. Sequence highlighted in blue is the restriction recognition site with the red letters 





In a total reaction of 25 µl; 1X Green GoTaq PCR buffer (Promega, Madison, WI, USA), 3 mM of 
MgCl2 (Promega, Madison, WI, USA), 0.2 mM Deoxynucleotide Triphosphates (dNTPs) (Celtic 
Molecular Diagnostics, Cape Town, SA), 0.4 µM of each primer (Integrated DNA Technologies, 
Illinois, USA), 1 unit Go-Taq (Promega, Madison, WI, USA), the reaction mix was topped up to 25 
µl using sabax deionised water (Adcock Ingram, Johannesburg, SA) and finally consisting of 100
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ng/µl DNA template. The thermal cycling T100™ Thermal Cycler (Bio-Rad Laboratories, California, 
USA) was used for DNA amplification. Cycling conditions were as follows: initial denaturation at 
94°C for 10 minutes, 94°C denaturation for 30 seconds, 58°C annealing for 30 seconds, 72°C 





VKORC1 c.3730G>A was genotyped using Sanger sequencing. The protocol used is as follows: 
firstly, the PCR products was purified from any unbound nucleotides. This was achieved by 
adding 1 unit FastAp thermosensitive Alkaline Phosphatase (Thermo Fischer Scientific, 
Massachusetts, USA), 4 units Exonuclease I (New England Biolabs®), 8.9 µl Sabax water (Adcock 
Ingram, Johannesburg, SA) and 15 µl in a PCR tube. The reaction mix was cleaned-up on the 
Thermal Cycler T100™ (Bio-Rad Laboratories, USA). The conditions were as follows: 37°C for an 
hour and 75°C for 15 minutes. 
 
After the PCR clean-up was completed, we proceeded to cycle sequencing. In a total reaction of 
10 µl; 0.4 µM reverse primer, 0.2X of BigDye® Terminator v3.1 dilution buffer (Life Technologies, 
CA, USA), 0.4X of BigDye® Terminator Sequencing Buffer (Thermo Fischer Scientific, 
Massachusetts, USA), 2 µl Sabax water (Adcock Ingram, Johannesburg, SA) and 3 µl cleaned-up 
PCR product were added. We used the GeneAmp® PCR System 9700 from Applied Biosystems 
(Thermo Fischer Scientific, Massachusetts, USA) to perform sequencing. Initial denaturation at 
98°C for 5 minutes, for 35 cycles- denaturation at 95°C for 30 seconds, annealing at 55°C for 15 
seconds and extension at 60°C for 4 minutes. 
 
After the completion of sequencing, ethanol precipitation followed. Samples were transferred to 
1.5 ml Eppendorf tube. 50 µl cold 100% ETOH and 2 µl of 3 M NaOAc pH5.2 were added to the 
1.5 ml sample tubes and kept overnight at -20°C. On the following day, samples were spun at 10 
000rpm for 10 minutes (Centrifuge 5415D; Eppendorf AG, Hamburg, Germany) and the 
supernatant removed. 35 µl of 70% ice-cold ETOH was added and sample centrifuged at 10 
000rpm for 10 minutes (Centrifuge 5415D; Eppendorf AG, Hamburg, Germany). The supernatant 









After ethanol precipitation, capillary electrophoresis preceded. 10 µl Hi-Di formamide was added 
to the PCR tubes, vortexed and denatured on the thermal cycling T100™ Thermal Cycler (Bio-Rad 
Laboratories, USA) at 95°C for 5 minutes. Samples must be cooled down immediately in a frozen 
coolant for 2 minutes. Using the ABI3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA), capillary electrophoresis was performed and using DNAstar® program we were able to 
perform gene annotation. 
 
GGCX c.1218C>T and c.1242C>T 
 
GGCX is located on chromosome 2p11.2 and consists of 15 exons. GGCX c.1218C>T and 
c.1242C>T are located on exon 9 and are 24 bp apart. Described below are the PCR conditions. In 
a total reaction of 25 µl; 1X Green GoTaq PCR buffer (Promega, Madison, WI, USA), 3 mM of 
MgCl2 (Promega, Madison, WI, USA), 0.2 mM Deoxynucleotide Triphosphates (dNTPs) (Celtic 
Molecular Diagnostics, Cape Town, SA), 0.4 µM of each primer (Integrated DNA Technologies, 
Illinois, USA), 1 unit Go-Taq (Promega, Madison, WI, USA), the reaction mix was topped up to 25 
µl using sabax deionised water (Adcock Ingram, Johannesburg, SA) and finally consisting of 100 
ng/µl DNA template. The thermal cycling Thermal Cycler T100™ (Bio-Rad Laboratories, California, 
USA) was used for DNA amplification. The cycling conditions included initial denaturation at 94°C 
for 3 minutes, in a total of 35 cycles, 94°C denaturation for 30 seconds, 56°C annealing for 30 




GGCX c.1218C>T and GGCX c.1242C>T were genotyped using Sanger sequencing. The protocol 
used is as follows: firstly, the PCR products was purified from any unbound nucleotides. This was 
achieved by adding 1 unit FastAp thermosensitive Alkaline Phosphatase (Thermo Fischer 
Scientific, Massachusetts, USA), 4 units Exonuclease I (New England Biolabs®), 8.9 µl Sabax water 
(Adcock Ingram, Johannesburg, SA) and 15 µl in a PCR tube. The reaction mix was cleaned-up on 
the Thermal Cycler T100™ (Bio-Rad Laboratories, USA). The conditions used were as follows: 
37°C for an hour and 75°C for 15 minutes. 
 
After the PCR clean-up was completed, we proceeded to cycle sequencing. In a total reaction of 
10 µl; 0.4 µM reverse primer, 0.2X of BigDye® Terminator v3.1 dilution buffer (Life Technologies, 
CA, USA), 0.4X of BigDye® Terminator Sequencing Buffer (Thermo Fischer Scientific,
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Massachusetts, USA), 2 µl Sabax water (Adcock Ingram, Johannesburg, SA) and 3 µl cleaned-up 
PCR product were added. We used the GeneAmp® PCR System 9700 from Applied Biosystems 
(Thermo Fischer Scientific, Massachusetts, USA) to perform sequencing. Initial denaturation at 
98°C for 5 minutes, for 35 cycles- denaturation at 95°C for 30 seconds, annealing at 55°C for 15 
seconds and extension at 60°C for 4 minutes. 
 
After the completion of sequencing, ethanol precipitation followed. Samples were transferred to 
1.5 ml Eppendorf tube. 50 µl cold 100% ETOH and 2 µl of 3 M NaOAc pH5.2 were added to the 
1.5 ml sample tubes and kept overnight at -20°C. On the following day, samples were span at 10 
000rpm for 10 minutes (Centrifuge 5415D; Eppendorf AG, Hamburg, Germany) and the 
supernatant removed. 35 µl of 70% ice-cold ETOH was added and sample centrifuged at 10 
000rpm for 10 minutes (Centrifuge 5415D; Eppendorf AG, Hamburg, Germany). The supernatant 
was removed and samples air-dried for at least 4 hours. 
 
After ethanol precipitation, capillary electrophoresis preceded. 10 µl Hi-Di formamide was added 
to the PCR tubes, vortexed and denatured on the thermal cycling T100™ Thermal Cycler (Bio-Rad 
Laboratories, USA) at 95°C for 5 minutes. Samples must be cooled down immediately in a frozen 
coolant for 2 minutes. Using the ABI3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA), capillary electrophoresis was performed and using DNAstar® program we were able to 
perform gene annotation. 
 
2.3 Data analysis/Statistical analysis 
 
Descriptive statistics was performed using GraphPad Prizm version 5. Stata™ version 11 was used 
to identify correlation between categorical predictor and independent variables. For association 
between categorical variables, the Chi square (X2) test was performed. The X2 test was used to 
assess whether the genotype frequencies were under Hardy-Weinberg equilibrium. Weekly 
warfarin maintenance dose was summarised as means together with standard deviations. These 
means were compared among the patients considering dose requirements of different 
genotypes using a t-test and analysis of variance (ANOVA). Statistical significance was considered 







Chapter 3: Results 
 
3.1 Participant clinical and demographic features 
 
A total of 372 South African black (SAB) and Mixed Ancestry (MA) participants were eligible for 
the study. There were more females on warfarin therapy than males, in both ethnic groups 
(Table 3.1). A statistically significant difference in age was observed between MA and SAB 
participants, p<0.0001. There was marginal distribution of smokers between genders, 53% 
female and 47% male smokers. However, there were more MA smokers (62%) than SAB smokers 
(20%). Differences were also seen in alcohol consumption. There was a high 59% incidence for 
female alcohol consumers compared to the 40% observed for male alcohol consumers within the 
MA group. Whereas in the SAB, the incidence for male alcohol consumers was higher (52%) than 
the females (24%). Differences in alcohol consumption were also observed between the two 
ethnic groups in this study. MA had more alcohol consumers (47%) than SAB (30%), though it 













































Table 3.1: Demographic and clinical information for Mixed ancestry (MA) and South African black 
(SAB) participants 
 
      
MA 
     MA vs. 
    MA   SAB  SAB total SAB P      total              value             
  Males Females P  Males Females P    
  N=95 N=168 value  N=23 N=86 value    
Demographic             
variables             
Mean ± SD Age 
 56 ± 
59 ± 14,7 0,398 
58 ± 
48 ± 14,1 50 ± 14,1 0,452 50 ± 14,1 <0,0001  16,1 15,3            
             
Mean ± SD BMI 
 25 ± 
28 ± 6,1 0,003 
27 ± 




90 (56%) 0,616 
162 
13 (56%) 9 (10%) 0,202 22 (20%) 0,495  (44%) (62%)            
Alcohol consumer 
51 
73 (59%) 0,471 
124 
12 (52%) 21 (24%) 0,303 33 (30%) 0,422 
(41%) (47%)            
Clinical variables            
Warfarin indication:            










 (38%)  (31%)              








(12%)  (18%)              
Pulmonary embolism 8 (8%) 18 (11%) 0,095 
26 
0 9 (10%) 0,27 9 (8%) 0,142 (10%) 
            
Mechanical valve 40 
68 (41%) 
 108 


















thromboembolism                
             
Comorbidities:             
Bleeding 
 14 
36 (22%) 0,191 
50 
6 (26%) 19 (22%) 0,229 25 (23%) 0,202  (15%) (19%)            
Heart failure 
 31 
70 (42%) 0,384 
101 
9 (39%) 24 (27%) 0,303 33 (30%) 0,36  (33%) (38%)            
Other conditions:            
Hypertension 
 36 
78 (47%) 0,435 
114 
4 (17%) 35 (40%) 0,358 39 (36%) 0,412  (38%) (44%)            
Diabetes mellitus 
16 
30 (18%) 0,176 
46 
2 (9%) 9 (10%) 0,101 11 (10%) 0,154 
(17%) (18%)            




For warfarin indication, the most common indication in this study was mechanical valve 
replacement (MV), at least 40% of participants were on therapy because of MV. This is also seen 
between genders where 44% of male participants had MV as an indication for warfarin and 42% 
in females. The least frequent indication for warfarin was venous thrombosis (VT) which 
accounted for less than 1% of participants. Inevitably, participants were likely to experience 




The most common comorbidity in the study was hypertension, at least 35% of participants were 
treated for hypertension concurrently. More males were treated for hypertension (44%) than 
females (36%). Looking at the common comorbidity between the ethnic groups, hypertension 
remained the most common comorbidity. It was higher in the MA (44%) group than SAB (36%). 
Diabetes was more frequent in the MA (18%) than SAB (10%). Furthermore, statistical difference 
(p=0.027) was observed in gender for HIV positive status in the MA group. 
 
 
Weekly stabilising dose was correlated with participants’ variables (Table 3.2). From our study 
cohort, age was inversely associated with stabilising dose requirements in both MA and SAB 
cohorts (p<0.0001 and p=0.042, respectively). The association between BMI and stabilising dose 
requirements was only significant in the MA cohort (p=0.003). Finally, in the SAB group, we 




Table 3.2: Univariate analysis between clinical variables and weekly stabilising dose 
 
 MA  SAB  
Variable Correlation coefficient (95% 
P-value 
Correlation coefficient (95% P- 
 CI) CI) value   
Age -0,275 (-0,389 to -0,160) <0.0001 -0.102 (-0.201 to -0.036) 0.042 
BMI 0.097 (0.034 to 0.159) 0.003 -0.032 (-0.087 to 0.024) 0.255 
Gender -0.003 (-0.007 to 0.0009) 0.127 0.0007 (-0.002 to 0.004) 0.635 
Tobacco 
0.001 (-0.003 to 0.005) 0.639 0.00005 (-0.004 to 0.002) 0.720 
Smoker     
Alcohol 
0.003 (-0.001 to 0.007) 0.162 -0.001 (-0.004 to 0.002) 0.549 
consumer     
Warfarin 
0.0008 (-0.012 to 0.010) 0.888 0.007 (-0.003 to 0.017) 0.157 
Indication     
Bleeding 
0.0007 (-0.003 to 0.004) 0.687 0.003 (-0.0006 to 0.006) 0.116 
events     
Heart failure -0.002 (-0.006 to 0.002) 0.384 0.0005 (-0.003 to 0.004) 0.771 
Diabetes 
0.001 (-0.002 to 0.005) 0.429 -0.001 (-0.003 to 0.0008) 0.294 
Mellitus     
Hypertension -0.002 (-0.007 to 0.002) 0.274 -0.0005 (-0.004 to 0.003) 0.784 








3.2 Genetic analysis 
 
3.2.1 Sample preparation and genetic characterization 
3.2.1.1 DNA extraction and quality control 
 
DNA extraction was successful in 372 participants. Quality control was conducted on the blood 
samples after DNA extraction, using a modified salting out method adapted from (Gustafson et 






















Figure 3.1: 1% Integrity gel indicating an example of samples of SAB and MA participants. Lane 1 is the 100 bp 
(Thermo Fisher Scientific GeneRuler, Wilmington, DE, USA), molecular weight marker. Lane 2-8 samples showing the 
presence of DNA after DNA extraction. 
 
3.2.1.2 PCR-RFLP Gel Electrophoreses and Sanger sequencing results 
 
For VKORC1 c.-1639G>A genotype determination, PCR-RFLP method was used and 372 samples 
were successfully amplified. The wild-type G/G presented two bands: 124 bp and 167 bp. 
Heterozygotes, G/A, had three bands: 124 bp, 167 bp and 291 bp. The mutant genotype, A/A, 


















(A) (B)  
 
Figure 3.2: VKORC1 c.-1639G>A PCR – RFLP Gel Electropherogram (A) and Sanger Sequence chromatograph (B). 
 
Figure (A) represents a 3% agarose gel showing results of VKORC1 c.-1639G>A PCR amplicon digested with MspI 
restriction enzyme. Lane 1: 100 bp (Thermo Fisher Scientific GeneRuler, Wilmington, DE, USA) molecular weight 
marker. Lane 4 and 5: Wildtype (G/G). Lane 1 and 2: Heterozygous (G/A). Lane 3: Homozygous mutant (A/A). 
Validation of genotypes was performed using Sanger sequencing as seen on Figure (B). The red box indicates the 
SNP position with different peaks for the possible bases. 
 
 
VKORC1 c.1173C>T genotype characterisation was determined by PCR-RFLP method was used 
and 372 samples were successfully amplified. The wild-type genotype C/C was identified by the 
353 bp band. The heterozygotes, C/T, were identified by two bands: 353 bp and 310 bp, the 43 
bp band could not be visualised. The homozygous mutant T/T was identified by the 310 bp band 
and 43 bp which could not be visualised. Using the 100 bp molecular weight marker (Figure 3.3), 
all bands were the expected sizes. 
 
For VKORC1 c.3730G>A genotyping, Sanger sequencing, method was used. Using the reverse 
primer, clear peaks (Figure 3.4) were visible to identify genotypes. Heterozygotes were 






































Figure 3.3: VKORC1 c.1173C>T PCR – RFLP Gel Electropherogram. A 3% agarose gel showing results for VKORC1 
 
c.1173C>T PCR amplicon digested with Hinf I restriction enzyme. Lane 1: 100 bp GeneRuler, (Thermo Fisher Scientific 
 
Wilmington, DE, USA) molecular weight marker. Lane 2 and 3: Homozygous mutant (T/T). Lane 4, 7, 8 and 9: Wildtype 
 




















Figure 3.4: VKORC1 c.3730G>A chromatograph. After Sanger sequencing, chromatograph indicates the variation of 
peaks which represent different genotypes for this SNP. 
 
 
In the GGCX gene, we identified two SNPs which were 24bp apart; GGCX c.1218C>T and GGCX 
c.1242C>T, respectively. The frequency of GGCX c.1218T was 0.179 in SAB and 0.134 in MA. For GGCX 
c.1242T the frequency was 0.087 in SAB and 0.122 in MA. Figure 3.5 shows a chromatograph 



































3.2.2 Genotype and allele frequencies 
 
After PCR-RFLP and Sanger sequencing, participant genotype frequencies were determined 
(Table 3.3). The chi square test was used to validate if genotypes are in HWE. In the SAB, VKORC1 
c.1173C>T and GGCX c.1218C>T were the only SNPs in Hardy Weinberg equilibrium (HWE); 
whereas in the MA, GGCX c.1218C>T was the only SNP not in HWE. The SNPs that were not in 
HWE suggests that there was possibly a type 1 error (genotyping error), this is seen with p values 


































Table 3.3: Observed genotype frequencies distribution of MA and SAB and patients 
 
   SAB   MA  
 SNP Genotype  Genotype 
P-value 
 Genotype 
P-value     frequency  frequency        
 
*VKORC1 
G/G 90 0.83  130 0.5  
 
G/A 16 0.15 0.046 106 0.4 0.52  c.-1639G>A  




    
 
*VKORC1 
C/C 80 0.73  141 0.54  
 C/T 28 0.26 0.39 95 0.36 0.1  c.1173C>T  




    
 
*VKORC1 
G/G 42 0.39  73 0.28  
 
G/A 39 0.36 0.004 127 0.48 0.791  c.3730G>A  




   
    
 
*GGCX 
C/C 48 0.59  127 0.58  
 C/T 27 0.33 0.43 70 0.32 0.02  c.1218C>T  




    
 
*GGCX 
C/C 65 0.8  160 0.73  
 C/T 13 0.16 0.043 52 0.24 0.481  c.1242C>T  




      
Note=* N=109 for SAB and N=263 for MA. Samples did not always add up to these totals due to errors 
that occurred with SNP characterization. 
 
 
We further determined the minor allele frequency and compared it with other populations to 
see if there are any similarities in the distribution of the frequencies (Table 3.4). The distribution 
of the mutant alleles varies across populations. Higher frequencies of the VKORC1 variants were 
observed in the MA group compared to SAB, for example, in VKORC1 c.-1639A (0.302 in MA vs. 
0.101 in SAB). Differences were observed with the GGCX variants. For GGCX c.1218T, a higher 
frequency is observed in SAB compared to MA (0.179 and 0.134, respectively). While GGCX 























Table 3.4: Allele frequency table representing frequencies of different populations compared 
with our study cohort 
  
 
Minor allele frequency 
 
Variant SAB MA Yoruba Caucasian Asian 
Afr 
SNP American 
allele N=109 N=263 N=113 N=113 N=43  N=347        
VKORC1 c.- 
A 0,101 0,302 0,025 0,387 0,941 0,125 
1639G>A        
VKORC1 
T 0,138 0,281 0,022 0,398 0,941 0,13 
c.1173C>T        
VKORC1 
A 0,257 0,468 0,535 0,362 0,058 0,402 
c.3730G>A        
GGCX c.1218C>T T 0,179 0,134 0,406 0,335 0,349 0,222 
GGCX c.1242C>T T 0,087 0,122 0,009 0,121 0,035 0,098 
 
Note: N=number of participants; Afr American=African American; SNP=single nucleotide 
polymorphism 
 
Surprisingly, the SAB and Yoruba populations had different frequencies though they are of 
African descent we would expect similar observations. VKORC1 c.-1639A is more frequent in 
Asian populations (0.941) compared to populations of African descent such as Yoruba (0.025). 
Similarly, Asian populations have a high frequency of VKORC1 c.1173T (0.941) than African 
descent populations, for instance, Yoruba (0.022). VKORC1 c.3730A was more prevalent in 
African descent populations, for instance, Yoruba (0.535), MA (0.468) and less common in Asian 
populations (0.058). 
 
GGCX c.1218T is comparable between Asians and Caucasians (0.349 and 0.335, respectively) 
however, differences are observed in our South African cohort (0.179 in SAB and 0.134 in MA). 
For GGCX c.1242T, higher frequency is observed in the MA group compared to other populations 
like Yoruba where it is prevalent at a lower frequency (0.009). 
 
 
3.3 Identified SNPs and their relationship with stabilising warfarin weekly dose 
requirements 
 
Weekly stabilising dose requirements for different genotypes were determined (Table 3.5). We 
observed that the SAB participants required higher warfarin doses across all genotypes relative 
to MA participants. This could be the result of cultural differences that affect diet and lifestyle 
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habits. We observed a higher incidence of HIV positive patients within the SAB group (22% vs. 
3%) with the HIV treatment potentially affecting warfarin response resulting in the higher 
warfarin dose requirements. Further investigation should assess the role of HIV treatment and 
warfarin response. Statistical difference observed in dose requirements in the MA cohort for 
VKORC1 c.-1639G>A, VKORC1 c.1173C>T and VKORC1 c.3730G>A (p<0.0001, p<0.0001 and 
p=0.002, respectively). Given the statistical difference observed for these genotypes, if we 
assess the daily dose requirements for one of these genotypes (i.e VKORC1 c.1173T/T) it 
averages to 3.6 mg/day, this is lower than the current prescribed dose at Groote Schuur Hospital 
or Gugulethu Community Health Centre of 5 mg/day. This indicates the need for population 
specific algorithms. There was no statistical difference in dose requirements in the SAB cohort 
for our SNPs of interest, a larger sample size could possibly increase statistical power. VKORC1 
c.-1639A and VKORC1 c.1173T are associated with warfarin sensitivity resulting in lower warfarin 
dose requirements. However, in SAB for these variants, higher doses were observed. This is 
because for VKORC1 c.1639A/A, the mean dosage was obtained from one out of the three 
individuals due to missing data in patient folders. For VKORC1 c.1173T/T, there was only one 
individual with this genotype and we therefore cannot conclude on the findings because a larger 





Table 3.5: Weekly stabilising dose requirements for SNP genotypes 
 
   Average stabilising dose in mg/week ± SD (N)  
 
A/O 
        
SNP  Mixed Ancestry   South African Black  
          
  AA 
AO 
OO P- AA AO OO P- 
    value    value         
VKORC1   c.- G/A 38 ± 14 31 ± 15 20 ± 14 <0.00 46 ± 31 41 ± 14 73 ± 0 
0.289 
1639G>A  (130) (106) (26) 01 (90) (16) (3)   
VKORC1 C/T 38 ± 15 29 ± 14 25 ± 13 <0.00 47 ± 31 41 ± 15 50 ± 0 
0.757 
c.1173C>T  (141) (95) (26) 01 (80) (28) (1)   
VKORC1 G/A 29 ± 15 34 ± 15 38 ± 16 
0.002 
42 ± 13 45 ± 28 54 ± 44 
0.558 
c.3730G>A  (73) (127) (59) (42) (39) (28)    
GGCX C/T 31 ± 15 36 ± 16 35 ± 15 
0.175 
42 ± 16 47 ± 32 38 ± 6 
0.949 
c.1218C>T  (127) (70) (21) (48) (27) (6)    
GGCX C/T 34 ± 16 31 ± 14 31 ± 16 
0.527 
44 ± 23 43 ± 14 43 ± 22 
0.558 
c.1242C>T  (160) (52) (6) (65) (13) (3)     
Note: SNP=single nucleotide polymorphism, N=number of participants genotyped for each SNP, A=alternate 
allele, and O= variant allele 
 
Genetic variants were correlated with stabilising weekly warfarin dose (Table 3.6). In the SAB 
participants, there was no association of the SNPs with weekly stabilising dose requirements. 
However, in MA participants, again the VKORC1 SNPs showed statistical association with dose 
requirements. VKORC1 c.-1639G>A and VKORC1 c.1173C>T were inversely associated with 
weekly stabilising dose requirements indicating warfarin sensitivity thus lower dose 
requirements. In addition, VKORC1 c.3730G>A was associated with higher weekly stabilising dose 




Table 3.6: Correlation of weekly stabilising dose requirements with SNPs 
 
 MA (N=263)  SAB (N=109)  
SNP Correlation coefficient 
P-value 
Correlation coefficient 
P-value  (95% CI) (95% CI)    
VKORC1 c.- 
-0.0137 (-0.019 to -0.008) <0.0001 -0.0003 (-0.004 to 0.003) 0.839 
1639G>A     
VKORC1 -0.0138 (-0.0192 to - 
<0.0001 -0.001 (-0.004 to 0.002) 0.550 
c.1173C>T 0.008)    
VKORC1 
0.0103 (0.004 to 0.016) <0.001 0.004 (-0.002 to 0.0102) 0.147 
c.3730G>A     
GGCX 
0.005 (-0.0001 to 0.116) 0.102 0.001 (-0.006 to 0.008) 0.755 
c.1218C>T     
GGCX 
-0.003 (-0.007 to 0.002) 0.247 -0.004 (-0.009 to 0.002) 0.218 
c.1242C>T     
N=number of participants genotyped for each SNP, SNP=single nucleotide polymorphism 
 
A multivariate analysis was conducted for the SNPs with weekly stabilising dose requirements 
(Table 3.7) for MA participants. VKORC1 c.-1639G>A was inversely associated with weekly 
stabilising dose requirements (p=0.003). The mutant genotype required a lower weekly warfarin 
stabilising dose (Figure 3.6), than the current prescribed dose (35 mg/week) in Groote Schuur 
Hospital and Gugulethu Community Health Centre. For the MA participants, the VKORC1 c.-
1639G>A SNP proved to be an important SNP which should be considered when initiating 
genotype-guided dosing. With our SNPs of interest, there was no association observed with SAB 
and weekly warfarin stabilising dose requirements. This suggests that these SNPs were not 
significant in dose requirements for SAB participants, therefore, other SNPs should be 
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Figure 3.6: Graphic representation of weekly stabilising dose requirements in MA. Association of weekly stabilising 























SNP Correlation coefficient (95% CI) P-value 
VKORC1 c.-1639G>A -7.5464 (-12.4494 to -2.6435) 0.003 
VKORC1 c.1173C>T -0.5645 (-5.3652 to 4.2363) 0.817 
VKORC1 c.3730G>A 1.3626 (-1.9070 to 4.6323) 0.412 
GGCX c.1218C>T 1.6990 (-1.40242 to 4.8005) 0.563 
GGCX c.1242C>T -1.2379(-5.4506 to 2.9749) 0.563 
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Chapter 4: Discussion 
 
Genomic markers associated with dose requirements among African populations and those of 
mixed ancestry origin in the Western Cape Province, South Africa, could possibly explain the 
differences in drug response including warfarin response. With observation we recruited 
participants from Groote Schuur Hospital (n=407) and Gugulethu Community Health Centre 
(n=46). With the disproportion of patients in GSH, we applied at the Western Cape Government 
for approval to recruit patients in GCHC to increase the number of SAB patients. Recruitment in 
GSH was quicker than in GCHC. This is because (1) the clinic is open Monday to Thursday (2) at 
least 20 patients are seen on each day (3) in GSH, 407 patients were recruited and in GCHC, 47 
patients were recruited and (5) the clinic in GCHC is open only on Mondays with few patients 
seen on that day. Duration of recruitment in GSH was from October 2015 to November 2015 
while in GCHC recruitment was only in June 2016. A total of 81 patients were excluded from 
genetic analysis for the following reasons: (1) Unsuccessful DNA extraction resulting in the loss of 
DNA due to DNA extraction protocol not adhered to, (2) Pharmacogenetics of Caucasian and 
Asian populations has been extensively studied therefore these patients were not included in this 
study and (3) Patients younger than 18 years.  The participants self-identified their ancestry as 
either black African or Mixed Ancestry from the identity of their families through 3 generations. 
The final sample size was 372 participants of which 263 were of Mixed Ancestry (MA) descent 
and 109 South African Black (SAB) participants. The participants were mostly recruited from 
Groote Schuur Hospital located in the Cape metropolitan area. 
 
 
The Cape metropolitan is a rapidly growing low-to-middle-income area of South Africa. The rapid 
growth has also increased the burden of cardiovascular disease (CVD) with risk factors including 
smoking, high cholesterol, obesity, diabetes, high blood pressure and physical inactivity (Smith, 
Ralston and Taubert, 2012). In addition, this upsurge has been attributed to progressive 
urbanization which has promoted unhealthy lifestyles (Press et al., 2010). Accordingly, the major 
indication for warfarin in this study was mechanical valve replacement (> 40%) likely due to heart 
conditions as expected in sub-Saharan Africa (Cappuccio and Miller, 2016). While warfarin 
remains the drug of choice in this area. Interestingly, in South African studies by Schapkaitz and 
Sithole. (2017) and Sonuga et al. (2016), the common indication for warfarin indication was atrial 





Similar results were observed in a Chinese study by Liu et al. (2017), atrial fibrillation was the 
most common indication (33.3%) (Liu et al., 2017). Nielsen et al. (2017) also reported on atrial 
fibrillation as the most common indication (54%) in a Danish study by (Nielsen et al., 2017). 
 
 
The primary goal of warfarin therapy is to maintain a stable International normalised ratio (INR) 
with the lowest effective dose possible (Kuruvilla and Gurk-Turner, 2001; Pirmohamed, 2013). 
For this study, weekly stabilising warfarin dose requirements was inversely associated with age in 
the MA and SAB groups (p<0.0001 and p=0.042, respectively). Similar findings were observed in a 
study by Khoury and Sheikh-Taha. (2014), where warfarin maintenance dose was lower in older 
patients (Khoury and Sheikh-Taha, 2014). These findings correspond with published literature, 
warfarin dose requirements decrease with increasing age (Merli, 2005; Singla and Morrill, 2005; 
Whitley et al., 2007). This is as a result of decreased metabolic activities, serum proteins and 
renal excretion (Crooks et al., 1976) in older patients. Consequently, the persistence of the drug 
in the body is increased by the changes in the drug pharmacokinetics resulting in increased drug 
sensitivity among older patients (Miura et al., 2009). 
 
For this study, BMI had an influence on weekly stabilising warfarin dose requirements in the MA 
group (p=0.003) with a weak correlation r=0.246. similar findings were reported in an African-
American population study, Whitley et al (2007), where a weak correlation (r=0.08) was observed 
between Total Weekly warfarin Dose (TWD) and BMI (Whitley et al., 2007). On the other hand, 
BMI had no influence on weekly stabilising warfarin dose in the SAB group. This was consistent 
with previously reported studies that found no relationship between BMI and warfarin dose 
requirements (Oates et al., 1998; Blann et al., 1999). These contradicting results makes it 
challenging to draw on a firm conclusion on the effects of BMI and warfarin stabilising dose. 
Conflicting results are also observed when assessing the effects of warfarin stabilising dose and 
variables such as tobacco smoking, alcohol consumption and warfarin indication. 
 
Firstly, tobacco smoking had no effect (p>0.6) on stabilising warfarin dose. In a systemic review 
by Nathisuwan et al. (2011) conflicting evidence on the effects of smoking on warfarin dosage 
was gathered (Nathisuwan et al., 2011). In their investigation, some studies suggested a 
significant 12% increase in warfarin dose requirements among smokers (Millican et al., 2007; 
Gage et al., 2008; Lenzini et al., 2008). This interaction with warfarin may increase warfarin 
clearance and reduce its effect (Lucas and Martin, 2013), thereby promoting dose increase. 
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Other studies found no association with smoking (Lee et al., 2005; Aquilante et al., 2006; Whitley 
et al., 2007). 
 
Secondly, alcohol consumption had no effect (p>0.1), however, Roth et al. (2012) reported an 
association between alcohol and major bleeding risk (p=0.04) (Roth et al., 2015). Weathermon 
and Crabb. (1999) suggest that alcohol should be avoided completely during warfarin therapy 
(Weathermon and Crabb, 1999). This is because alcohol has the likelihood to increase warfarin 
anticoagulation effects which will increase the INR, thereby increasing the risk of haemorrhage 
(Ilaris et al., 2009). However, if alcohol is consumed within normal limits it is safe (Ilaris et al., 
2009). It is therefore important to educate patients to avoid excessive use of alcohol (Sonuga et 
al., 2016). 
 
Finally, we did not have any association of warfarin indication with stabilising warfarin dose for 
this study. However, Anderson et al. (2004) found lower warfarin dose requirements for patients 
who suffered from stroke and this is a result of undernutrition which is expected after stroke 
(Andersson et al., 2004). In addition, Limdi et al. (2009) found that patients with severe chronic 
kidney disease required significantly low warfarin dose (p=0.002) (Limdi et al., 2009). Moreover, 
Lenzini et al. (2010) found that lower warfarin requirements were recommended when using 
diabetes as a marker (Lenzini et al., 2010) and this was consistent with previously published 
literature (Hillman et al., 2004). In contrast, comorbidities had no effect on warfarin dosing in 
this study. 
 
Warfarin remains the drug of choice for anticoagulant treatment. The metabolism of warfarin is 
affected by genetic polymorphisms in cytochrome P450 2C9 (CYP2C9) and vitamin k reductase 
complex 1 (VKORC1) both of which account for 30%-40% of warfarin dose variation (Bodin et al., 
2005; Sconce et al., 2005; Vecsler et al., 2006). Candidate genes that have been identified include 
gamma-glutamyl carboxylase (GGCX), epoxide hydrolase 1 (EPHX1), calumenin (CALU) and 
CYP2C19 (Wadelius et al., 2007; Luxembourg et al., 2010; Huang et al., 2011). Some of these 
genes were not screened for because of time constraints. 
 
4.1 Correlation between genetic variation and warfarin stabilising doses 
 
In the present study, we focused on SNPs found in two genes (VKORC1 and GGCX). Firstly, in the 
VKORC1 gene, the allele frequency for VKORC1 c.-1639A was observed at 10% in SAB. Geisen et 
al. (2005) observed similar findings in an African American study with a frequency of 14% (Geisen 
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et al., 2005). In addition, an Egyptian study by Ghozlan et al. (2005) also observed a frequency of 
10% (Ghozlan et al., 2015). These similar findings are expected because these populations are of 
African descent and therefore may have a common ancestor. In the MA, VKORC1 c.-1639A 
frequency was 30%, similar to observations in a US study by Budnitz et al. (2007) were they 
observed a frequency of 29.7% (Budnitz et al., 2007). However, higher frequencies (84%) were 
observed in an Asian population (Li et al., 2015). From the VKORC1 c.-1639G>A genotypes, the 
highest mean weekly stabilising warfarin dosages in this study was given to carriers of the A/A 
genotype, while carriers of the heterozygous genotype G/A were treated with lower mean 
weekly stabilising warfarin dosages (73 ± 0 mg/week and 41 ± 14 mg/week, respectively) in SAB. 
Dosages from only one individual of the A/A genotype were available. However, in the MA group, 
there was significant mean weekly dose requirements for the VKORC1 c.-1639G>A (p<0.0001). 
The highest mean weekly stabilising warfarin dosages was given to carriers of the G/G genotype 
(wild-type), while carriers of the mutant genotype A/A were treated with lower dosages (38 ± 14 
mg/week and 18 ± 14 mg/week, respectively) which is equivalent to (5.4 ± 2 mg/day and 2.6 ± 2 
mg/day, respectively). In a study by Natarajan et al. (2013), carriers of the G/G genotype received 
higher daily doses than A/A genotype carriers (4.7 mg/day and 2 mg/day, respectively) 
(Natarajan et al., 2013). The higher dose requirement for the G/G was also seen in this study. 
 
Secondly, for VKORC1 c.1173T, a 14% allele frequency was observed in SAB and 28% in MA. 
Mclellan et al. (2011) observed a 4% frequency in a South African black population (Mclellan et 
al., 2011). In addition, Takahashi et al. (2006) observed a frequency of 8% in African Americans 
which was lower than observations in Caucasians and Asians (42% and 89%, respectively) 
(Takahashi et al., 2006). For VKORC1 c.1173C>T, the carriers of the T/T genotype in SAB required 
higher mean stabilising warfarin dose and lower mean stabilising warfarin dosages were 
administered to C/T genotype (73 ± 0 mg/week and 41 ± 14 mg/week, respectively), this is 
because there was only one individual with the T/T genotype in SAB. In comparison, in the MA 
group, significant mean dose requirements for the VKORC1 c.1173C>T were observed 
(p<0.0001). The C/C genotype received higher mean weekly stabilising warfarin dosages than the 
T/T genotype (38 ± 15 mg/week and 25 ± 13 mg/week, respectively). Different findings were 
observed by Kianmehr et al. (2010) in an Iranian population where the C/C and T/T genotype 
each received weekly warfarin dose of 26.4 ± 15.8 mg/week and 15 ± 6.2 mg/week, respectively 
(Kianmehr et al., 2010). A negative association was observed for VKORC1 c.-1639G>A and 
VKORC1 c.1173C>T and weekly stabilising warfarin dose in SAB. While a significant negative 
association was observed for VKORC1 c.-1639G>A and VKORC1 c.1173C>T in the MA group 
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(p<0.0001) with mean weekly stabilising warfarin dose indicating low dose phenotypes. Similarly, 
Geisen et al. (2005) found comparable results (Geisen et al., 2005). On the other hand, for 
VKORC1 c.3730G>A, a positive association was observed in SAB and a significant positive 
association was observed in MA (P<0.001) with weekly stabilising warfarin dose requirements. 
Kringen et al. (2011) observed similar findings were VKORC1 c.3730G>A was associated with high 
warfarin dose phenotype (Kringen et al., 2011). 
 
 
Lastly, for VKORC1 c.3730A the SAB the allele frequency was 26% and 47% in MA. Interestingly, 
similar findings to the MA, a South African black population frequency (40%) was observed 
(Mclellan et al., 2011). Limdi et al. (2008) observed frequencies of 20.3% in African Americans 
while Takahashi et al. (2006) observed a frequency of 52% (Takahashi et al., 2006; Limdi et al., 
2008). It is interesting to note the differences in frequency distribution among these populations 
of African descent is likely due to differences in sample size. For VKORC1 c.3730G>A 
polymorphism which is associated with warfarin resistance, carriers of the A/A genotype were 
administered higher mean weekly warfarin doses than G/G carriers (wild-type) (54 ± 44 mg/week 
and 42 ± 13 mg/week, respectively) in SAB. In MA, A/A carriers received higher mean weekly 
warfarin dosages than the wild-type G/G genotype (38 ± 16 mg/week and 29 ± 15 mg/week, 
respectively). Cini et al. (2012) had different observations for mean weekly dose requirements 
for A/A and G/G genotypes (56.7 ± 13.3 mg/week and 25.3 ± 8.8 mg/week, respectively) (Cini et 
al., 2012) but they also agree to the warfarin resistance association with this SNP. 
 
The GGCX gene has not received much attention. To our knowledge, this is the first study on 
GGCX variation and its correlation with warfarin among African populations. For this gene, we 
were interested in the 1218C>T and 1242C>T SNPs. For the GGCX c.1218T variant, the frequency 
was 18% in SAB and 13% in MA. In an Asian population study by Kamali et al. (2013), they 
observed a frequency of 28% (Kamali et al., 2013). In addition, Shikata et al. (2004) in a Japanese 
population observed a frequency of 68% (Shikata et al., 2004). For the GGCX c.1242T we 
observed a frequency of 8% in SAB and 12% in MA. The observation in SAB was similar to a 
Japanese study by Shikata et al. (2004) where they observed a frequency of 6% (Shikata et al., 
2004). These SNPs are not commonly studied thus, limited literature is available. The probable 
reason for this is that the clinical effect of these SNPs is benign. When looking at the GGCX gene; 
for GGCX 1218C>T in SAB, though not statistically significant, there were differences in mean 
weekly warfarin dosage administration observed in heterozygous C/T genotype and T/T genotype 
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(47 ± 32 mg/week and 38 ± 6 mg/week, respectively). In the MA group, heterozygous C/T 
genotype received higher mean warfarin dosages than C/C genotype (36 ± 16 mg/week and 31 ± 
15 mg/week, respectively). These findings were different than observations made by Kamali et al. 
(2010) in an Asian population. They found that the T/T genotype required higher doses than the 
C/C genotype (28.4 ± 6.2 mg/week and 20 ± 4.3 mg/week, respectively) (Kamali and Wynne, 
2010). For GGCX c.1242C>T, carriers of the C/C genotype received higher doses than C/T 
genotypes (44 ± 23 mg/week and 43 ± 23 mg/week, respectively) in SAB. Similarly, in the MA 
group, carriers of C/C genotype received higher doses than C/T genotype (34 ± 16 mg/week and 
31 ± 14 mg/week, respectively). Furthermore, for the GGCX c.1242C>T SNP, we observed a 
negative association with weekly stabilising dose in both groups (r=-0.004 in SAB and r=-0.003 in 
MA). More genetic analysis should be done on this SNP among diverse populations to find the 
effect it has on stabilising dose. 
 
With multivariate analysis, we assessed the effect of our SNPs of interest on weekly stabilising 
dose requirements in the MA group since significant association was observed in some of the 
SNPs. VKORC1 c.-1639G>A maintained significant negative association with stabilising dose 
requirements. This emphasised the warfarin low dose phenotype. As a result, VKORC1 c.-





We had a small sample size for the SAB (n=109) compared to the MA (n=273). This small sample 
size may not have been enough to extrapolate the findings on warfarin dose treatment. This 
limitation was a result of failure in DNA extraction for this group. In addition, some participants 



















From this study, we determined allelic variants of VKORC1 and GGCX in a South African 
population. To our knowledge, variants alleles of GGCX have not been reported in an African 
population. The GGCX variant alleles can be used in future studies particularly of African descent 
to investigate any correlation with warfarin response. 
 
There was no genetic association for warfarin dose requirements with our SNPs of interest in the 
SAB group. However, we observed an association (p=0.033) of dose requirements in the MA 
group for VKORC1 c.-1639G>A SNP. Carriers of the G/G genotype had higher dose requirements 
(38 ± 14 mg/week) compared to carriers of the A/A genotype (18 ± 14 mg/week). 
 
From our observations, environmental factors such as age and BMI influenced warfarin dose 
requirements in this population. Age was inversely associated with weekly stabilising dose 
requirements (p>0.001 in MA; p>0.042 in SAB), with increasing age there is a lower dose 
requirement. In addition, it was only in the MA group that an association with weekly stabilising 
dose and BMI was observed (p=0.003). 
 
We conclude that both genetic and environmental factors may influence warfarin response in 
South African patients. Differences observed between MA and SAB population groups are likely 
due to underlying genetic markers for warfarin response. Therefore, functional studies may assist 
in the determination of the effect of these variants in cellular models. In addition, knowledge in 
the pharmacogenomics of warfarin can help improve warfarin therapy among South African 
patients. To achieve this, more genetic markers need to be characterized as it may assist in 
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STUDY TITLE: PHARMACOGENOMICS OF COUMARIN DRUGS: A FOCUS ON THE GENETIC 
DETERMINANTS AFFECTING WARFARIN RESPONSE 
 
PRINCIPAL INVESTIGATORS: Professor Collet Dandara and Professor Mpiko Ntsekhe 
 
OTHER STAFF INVOLVED: Zinhle Cindi, Edson Makambwa, Dr Miguel Larceda and Dr Lerato Mpye 
 






Hello, I am __________________________________*, a researcher in the Division of Human 
Genetics, UCT. I am approaching you because you are on treatment with a medication called 
Warfarin and I would appreciate it if you were to participate in this research project. I would be 
very grateful for your participation. Before agreeing to participate, it is important that you 
understand the following explanations of the purpose of the study, the study procedures, 
benefits, risks, discomforts, and precautions as well as your right to withdraw from the study at 
any time. This information leaflet is to help you to decide if you would like to participate. You 




Purpose of the study 
 
This study is being undertaken in order to find out what causes differences in the time it takes for 
patients on warfarin to reach a stable dose that is safe. We are asking whether patients getting 
different times to reach this safe dose also have different changes in their genes. Genes are the 
molecules in our bodies that tells us how to function. They are contained in DNA which is what 
each of us inherits from our parents. This DNA can be extracted from blood and can be used to 
tell us if there are any changes on the DNA that may be associated with the differences that we 
observe in drug response. If you decide to participate, you will not be asked to take any 







If you agree to participate, your medical information including demographic information 
will be accessed from the clinic files and you will be required to complete a 
questionnaire, one asking for information on your ethnicity and clinical records. 
 
A qualified nurse will draw 5 ml blood from you for the extraction of DNA that will be 
used for genetic analysis. Possible side effects which may be associated with obtaining a 
blood sample include pain, bruising, light-headedness and on rare occasions infection. 
Precautions will be taken to avoid these difficulties. The entire procedure should take 
approximately 10 minutes. 
 
Sample collection schedule 
 
After consenting to participate in the study, the following schedule will be followed for 
collection of study samples from you. 
 
Activity Duration Follow up 
  activity 
   
Interview 10- Blood 
 15min collection 
   
 
 
Unforeseen risks and potential benefits 
 
Regular medication will continue however, should you experience side effects please 
contact your doctor immediately. Your participation in the study does not have direct 
benefit, however, these findings may assist dosing for future patients. 
 
As a participant in the study you have the following rights: Your participation is 
completely voluntary and free. Should you participate, you are still free to withdraw from 
the study and there is no need to give reasons for your withdrawal. This will have no 
effect on the standard of care that you receive or your relationship with the doctor. The 
test results will be made available to you on your request. The results will be strictly 
confidential and published data will not have your name. 
 
Some of the methods used for DNA characterization have a potential to identify other 
genetic mutations that are known to be associated with other disease risks. 
 
Ethical approval: This clinical study protocol has been approved by the University of Cape Town, 
 





Source of additional information: Your prescribing doctor is still facilitating your care throughout 
the duration of the study whom you should contact at any time should you feel that any of your 
symptoms are causing you problems. Should you have questions relating to the study please 
contact Professor Dandara, on the following 021 406 6506 or 0849955010 and email: 
collet.dandara@uct.ac.za 
 


































































Participant name:   Participant number:  
I have read or heard the explanation of this study and I am willing to participate. 
Please indicate 

 your consent for the following:    






















____________________   
Participant’s signature Date  
____________________   
   
Witness signature Date  
____________________   
























PROJECT TITLE: PHARMACOGENOMICS OF COUMARIN DRUGS: A FOCUS ON THE GENETIC 








We need information about you, your parents and your grandparents in order to determine if 
there is any genetic difference in the metabolism of drugs between different Southern African 
populations. Please try to be as accurate as possible. The quality of data will depend on the truth 
of your response to the questions below. It is better to leave out information than to give us 






























































3. ABOUT YOUR GRANDPARENTS  
Your mother’s mother Your father’s mother 
Place of birth: ____________________________ ________________________________ 
Province or country: __________________________ _________________________ 






Your mother’s father Your father’s father 
 





























PHARMAGENOMICS OF WARFARIN QUESTIONNAIRE 
 
Participant name: Participant number:  
 
Please complete the following demographic information questionnaire and take note that your 
answers to the following questions will be used for research purposes only and will be kept 
strictly confidential. 
 
Date of birth (yyyy/mm/dd)         
Gender   Male  Female     
Ethnicity 

 (Please tick where applicable)       
Afrikaner    English Mixed ancestry Indian   Sipedi 
Sotho    Tswana Venda Swazi  Ndebele 
Tsonga    Xhosa Asian Other (specify)     
Height     Weight      
Do you smoke tobacco (tick √ )         
    How many       
• Yes 
  cigarettes per day       
  do you or did you                 
    smoke       
• In the past           
    If you have       
• No   stopped, when       
    was that?       
Do you consume alcohol 
How much alcohol       
per day or per 
      
(tick√)?           
week? 
      
          
    When did you       
• Yes   start       
    (month/year)       
• In the past           
    If you have       
• No   stopped, when       
    was that?       
What type of alcohol (tick√)? • Lager       
    • Wine       
    • Spirits       
    • Home-made       
    • Cider       
Level of Qualification 

None Primary High School Matric   Tertiary 
(Please tick where applicable) 
  
        
Employment   Still studying Employed Unemployed  Retired 
Type of employment          
Conditions indicated for: Atrial fibrillation Venous Prosthetic/mech Deep vein Pulmonary 

(Please tick where applicable)   thromboembolism anical valves thrombosis  embolism 
         
Initiation  date  for  treatment         
(yyyy/mm/dd)           
          
Number of warfarin dose          
adjustment before reaching INR 2nd dose 3rd dose 4th dose   More 
(mg/d)           
Date when INR was achieved (2 Date Dose INR (mg/d)      
weeks within target)          
           
Any bleeding events/ adverse Yes  No Date & description:    
reactions on warfarin          
         
Concomitant drugs use (Name         
and duration)           
Other  comorbidities  e.g.  blood Yes  No Comments:     
pressure, diabetes etc.          
          
Other parameters          
Adverse drug event  Date/comments       
Diet (any special diet,          
frequency of eating green         




















































































































































VKORC1 c.-1639G>A PCR-RFLP Protocol 
 
1.  PCR 
 
Reagents 
Volume (µL) Final 
Single reaction Concentration  
   
Template DNA (100 ng/µl) 1  
5X GoTaq Flexi PCR Buffer 
5 1X 
(Promega)   
   
25 mM GoTaq MgCl2 
3 3 mM 
(Fermentas)   
   
5 mM dNTPs 1 0.2 mM 
10 µM VKORC1 c.-1639G>A 
0.8 0.32 µM 
Forward Primer   
   
10 µM VKORC1 c.-1639G>A 
0.8 0.32 µM 
Reverse Primer   
   
5 U/µL Go Taq 0.1 1 unit 
Nuclease free water 13.3  
Total reaction volume 25  






1.2.1 Run the PCR on the BIoRadT100 Thermocycler using the following conditions: 
 
• Initial denaturation:  94°C for 10 minutes 
 
• Denaturation: 94°C for 1 minute 
• Annealing: 65°C for 1 minute 
• Extension: 72°C for 1 minute Repeat steps ii to iii 35 times 




1.2.2 Prepare a 1% agarose gel and add 20 µL/100ml 1X E-Z vision gel stain. Use the 100 bp 
(Thermo Fischer Scientific, Massachusetts, USA) ladder as your molecular weight marker. Run the 

















2.1 Prepare the digestion mix as follows: 
 
Reagents Volume Final 
 (µL) Concentration 
 Single  
 reaction  
   
PCR Product 10  
   
10 U/uL MsP1(Biolabs) 1 1 unit 
   
10X Cut Smart Buffer 3 1X 
(Biolabs)   
   
Nuclease free water 16  
   
Total reaction volume 30  
   
 
 
2.2 Run the digest in the water-bath at 37°C for 3 hours. 
 
2.3 Run the digests on a 3% agarose gel at 100 V for 2 hours. 
 
2.4 The expected genotype RFLPs are: 
 
Genotype Fragment 167 bp Fragment 124 bp Fragment 291 bp 
    
Homozygous G/G    
    
Heterozygous G/A ✓ ✓ ✓
    
Homozygous A/A   ✓

































 Volume (µL) 
Final 
Reagents Single 
Concentration  reaction   
   
Template DNA (100 ng/µl) 1  
   
5X GoTaq Flexi PCR Buffer (Promega) 5 1X 
   
25 mM GoTaq MgCl2 (Fermentas) 3 3 mM 
   
5 mM dNTPs 1 0.2 mM 
   
10 µM VKORC1 c.1173C>T Forward Primer 0.5 0.4 µM 
   
10 µM VKORC1 c.1173C>T Reverse Primer 0.5 0.4 µM 
5 U/µL Go Taq 0.1 1unit 
   
Nuclease free water 13.9  
   
Total reaction volume 25  
   
 
 
2.2.1 Run the PCR on the BIoRadT100 Thermocycler using the following conditions: 
 
• Initial denaturation:  94C for 10 minutes  
• Denaturation: 94°C for 1 minute 
• Annealing: 56°C for 1 minute 
• Extension: 72°C for 1 minute Repeat steps ii to iii 35 times 
• Final extension: 72°C for 10 minutes 
 
2.2.2 Prepare a 1% agarose gel and add 20 µl/100ml of 1X E-Z Vision gel nucleic acid stain). 
Use the 100 bp molecular marker (Thermo Fischer Scientific, Massachusetts, USA). Run the 




























2.1 Prepare the digestion mix as follows: 
 
 Volume (µL) 
Final 
Reagents Single 
Concentration  reaction   
PCR Product 10  
10 000 U/ml BsrBI (Biolabs) 1 1 unit 
   
10X   Cut   Smart   Buffer 
3 1X 
(Biolabs)   
Nuclease free water 16  
   
Total reaction volume 30  
 
 
2.2 Run the digest in the water-bath at 37°C for 3 hours. 
 
2.3 Run the digests on a 3% agarose gel at 100 V for 90 minutes. 
 
2.4 The expected genotype RFLPs are: 
 
Genotype Fragment 8 bp Fragment 43 bp Fragment 310 bp Fragment 353 bp 
Homozygous C/C        
Heterozygous C/T ✓ ✓ ✓ ✓













































 Volume (µL) 
Final 
Reagents Single 
Concentration  reaction   
Template DNA (100 ng/µl) 1  
   
5X GoTaq Flexi PCR Buffer (Promega) 5 1X 
   
25 mM GoTaq MgCl2 (Fermentas) 2.5 3 mM 
   
5 mM dNTPs 0.5 0.2 mM 
   
10 µM VKORC1 c.3730G>A Forward Primer 0.5 0.4 µM 
10 µM VKORC1 c.3730G>A Reverse Primer 0.5 0.4 µM 
   
5 U/µL Go Taq 0.1 1 unit 
   
Nuclease free water 14.9  
   
Total reaction volume 25  
 
 
2.3 Run the PCR on the BIoRadT100 Thermocycler using the following conditions: 
 
• Initial denaturation:  94°C for 10 minutes 
 
• Denaturation: 94°C for 30 seconds 
• Annealing: 58°C for 30 seconds 
• Extension: 72°C for 90 seconds Repeat steps ii to iii 35 times 




2.4 Prepare a 1% agarose gel. Use 100 bp the (Thermo Fischer Scientific, Massachusetts, USA 
ThermoFisher) ladder as your molecular weight marker. Run the gel for 1 hour at 100 V. The 






















GGCX c.1218C>T and GGCXc.1242C>T PCR Protocol 
 
 Volume (µL) 
Final 
Reagents Single 
concentration  reaction   
Template DNA (100 ng/µl) 1  
   
5X GoTaq Flexi PCR Buffer (Promega) 5 1X 
   
25 mM GoTaq MgCl2 (Fermentas) 3 3 mM 
   
5 mM dNTPs 1 0.2 mM 
   
10 µM Forward Primer 1 0.4 µM 
10 µM Reverse Primer 1 0.4 µM 
   
5 U/µL Go Taq 0.1 1 unit 
   
Nuclease free water 12.9  
   
Total reaction volume 25  
 
 
Run the PCR on the BIoRadT100 Thermocycler using the following conditions: 
 
• Initial denaturation:  94°C for 3 minutes 
 
• Denaturation: 94°C for 30 seconds 
• Annealing: 56°C for 30 seconds 
• Extension: 72°C for 1 minute Repeat steps ii to iii 35 times 
• Final extension: 72°C for 5 minutes 
 
Prepare a 1% agarose gel. Use 100 bp the (Thermo Fischer Scientific, Massachusetts, USA 
ThermoFisher) ladder as your molecular weight marker. Run the gel for 1 hour at 100 V. 































1. Preparation of post PCR clean up mix: 
 
 
 Volume (µL) 
Final 
Reagents Single 
concentration  reaction   
FastAp thermosensitive Alkaline Phosphatase (1 U/µL) 1 1 unit 
Exonuclease I (20 U/µL) 0.2 4 units 
Nuclease free water 13.8  
PCR Product 5  
Total reaction volume 20  
 
2. Perform the clean up using these conditions on the BioRad MyCycler Thermal Cycler: 
i. 37°C for 1 hour 
ii. 75°C for 15 minutes 
 
3. Using a 3% agarose gel, check the quality of the clean-up described 
 
4. Preparation of the sequencing mix (NOTE: master mix should contain one 
primer, either the forward or reverse primer) 
 
 
Reagents Volume (µL) Single reaction Final concentration 
   
10 µM Primer 1.0 0.4 µM 
   
2.5X Big Dye Terminator mix 2.0 0.2X 
   
5X Big Dye Sequencing Buffer 2.0 0.4X 
   
Nuclease free water 3.5  
   
Clean-up PCR Product 1.5  
Total reaction volume 10.0  
   
 
 
1. Using the ABI9700 Thermal Cycler, perform the sequencing reaction using 
these conditions: a. 98°C for 5 minutes  
b. 96 °C for 30 seconds 
c. 55°C for 15 seconds 
d. 60 °C for 4 minutes  
Repeat steps b and c for 35 cycles 
2. For a 10 µL sequencing reaction add 50 µL 100% ethanol into each tube and 2 µL sodium 
acetate (pH 5.2). 
 
3. Add sample to tubes, votex and leave overnight at -20°C. 
 
4. Spin the samples at 10 000rpm for 10 minutes. 
 




6. Add 35 µL of 70% ice cold ethanol to each tube, vortex and spin at 10 000rpm for 10 
minutes. 
 
7. Remove supernatant and leave to air dry for at least 4 hours. 
 
8. Add 10 µl of Hi-Di formamide once samples have dried. 
 
9. At 95°C denature the samples for 5 minutes. 
 
10. Cool the samples for 2 minutes in a frozen coolant. 
 
11. Proceed to capillary electrophoresis using the ABI3130xl Genetic Analyzer. 
 
12. Perform gene annotation using DNAstar® program. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
